The development and application of pyrosequencing assays to determine antiviral susceptibility of Influenza A to neuraminidase inhibitors. by Gatica-Wilcox, Bree
  
 
 
The Development and 
Application of Pyrosequencing 
Assays to Determine Antiviral 
Susceptibility of Influenza A to 
Neuraminidase Inhibitors. 
 
 
 
MPhil in Medicine 
 
March 2014 
 
Bree Gatica-Wilcox 
 
 i 
 
Summary: 
Influenza A can result in complicated disease and death in high risk individuals, 
and can be treated with the neuraminidase inhibitors oseltamivir and zanamivir. 
During the 2007-2008 season a rise in oseltamivir resistance in H1N1 viruses was 
observed worldwide. This resistance was caused by a point mutation in the 
neuraminidase gene segment at position 274 causing an amino acid change from 
histidine to tyrosine. Other point mutations have also been observed conferring 
resistance to neuraminidase inhibitors in H1N1 and H3N2 viruses, such as D151, 
E119V, R292K and N294S. Assays for the detection of resistance to the 
neuraminidase inhibitors have been well documented, the most novel being 
pyrosequencing. The aim of this study was to optimise pyrosequencing assays for 
routine use in a diagnostic laboratory. Once optimisation and validation were 
achieved using reference strains of influenza A, clinical validation was performed 
on influenza A isolates collected during the 2008-2009 season. Optimisation and 
clinical validation of a SNP pyrosequencing assay for the detection of the H274Y 
mutation in H1N1pdm09 isolates was also performed on isolates collected during 
the 2009-2010 and 2010-2011 seasons. Routine diagnostic assays were optimised 
for the H274Y mutation in pre 2009 H1N1 viruses and H1N1pdm09 viruses, and 
for the E119V mutation in H3N2 viruses. Only SQA assays were able to be 
optimised for the D151, R292K and N294S mutations in H3N2 viruses. Clinical 
validation showed that all seasonal H1N1 viruses isolated before April 2009 
possessed the H274Y mutation at nearly 100%. The E119V mutation was 
detected in nearly 50% of H3N2 samples tested at varying levels from 1% to 
31%. The D151, R292K and N294S mutations were not detected in any of the 
samples and the majority of the H1N1pdm09 samples contained a low level (1-
10%) of H274Y mutation in the viral quasi-species.  
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1. Introduction: 
Influenza A can result in complicated disease in high risk individuals and can 
lead to approximately 600 deaths in the UK each year (NHS, 2013). In the UK 
patients can be treated with the neuraminidase inhibitors, oseltamivir and 
zanamivir (Parry-Ford, 2013). Influenza viruses are highly prone to mutation due 
to their lack of a proof reading mechanism for RNA synthesis, during the 
replication process. When the neuraminidase inhibitors were first developed and 
introduced, single nucleotide point mutations were observed in challenge studies. 
The mutation of most interest was a change from CAT to TAT in codon 274, 
which resulted in an amino acid change form histidine (H) to tyrosine (Y), 
leading to a reduced susceptibility to oseltamivir in H1N1 viruses. An increasing 
number of clinical isolates containing this mutation was observed during the 
2007-2008 season. Reference testing for the presence of this mutation in patient 
samples who do not improve when given neuraminidase inhibitor treatment can 
be performed, but can take at least 3 days for a result. It was agreed that it would 
be more cost effective and better for patient management if this testing could be 
performed on site at the Molecular Diagnostics Unit, part of Microbiology Cardiff 
at the University Hospital Wales. It was therefore decided to adapt and optimise 
pyrosequencing assays recently published by Deyde et al (2009b), and the assay 
in use by the Respiratory Virus Unit, at the Health Protection Agency, Colindale 
(now Public Health England). Performing this type of assay as part of the routine 
testing algorithm for influenza viruses would allow the administration of 
appropriate antiviral treatment, in a timely manner, leading to better care and 
outcomes for patient management. 
1.1. Influenza Viruses: 
Influenza viruses are members of the Orthomyxoviridae family. There are 3 
genera of influenza, types A, B and C. The virions are pleomorphic and about 80-
120 nm in diameter. They consist of a helical nucleocapsid encased in an 
envelope derived from the plasma membrane of its host-cell. The genome is 
segmented into 8 parts (7 for type C) of negative sense, single stranded RNA 
which code for the viral proteins (10 for type A, 11 for type B and 9 for type C). 
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Segment 1 codes for the PB2 protein which enables host-cell RNA cap binding. 
Segment 2 codes for the PB1 protein, which is involved in the initiation of 
transcription and catalyses nucleotide addition and segment 3 codes for the PA 
protein which enables the elongation of mRNA chains. These 3 proteins are all 
components of RNA transcriptase (Lamb & Choppin, 1983). Segment 4 codes for 
the surface protein Haemagglutinin (H). Segment 5 codes for the nucleocapsid 
protein (NP) which enables the RNA segments to form ribonucleoproteins 
(RNPs). Segment 6 codes for the other surface protein Neuraminidase (N). 
Segment 7 codes for the M1 proteins which line the viral membrane and the M2 
ion channel proteins and segment 8 codes for the non-structural (NS) proteins, 
NS1 and NS2 (Figure 1) (Lamb & Choppin, 1983; White & Fenner, 1994; 
Wagner et al, 2008; Shors, 2013). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 1 - Influenza virus (Kaiser, 2006). Illustration of generic influenza virus 
structure and genome segments. 
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Influenza A virus is further divided into subtypes. These are defined by the 
serotype of H and N proteins. There are 17 different H proteins and 10 N proteins 
(Shaw & Palese, 2013; Tong et al, 2013). The H protein is a 550 amino acid 
polypeptide which forms tetramers (spikes) on the cell surface (Figure 1) 
(Zambon, 1999). The N protein is a 200kDa tetrameric protein which forms 
mushroom shaped protrusions on the cell surface (Figure 1) (Colman, 1994). The 
amino acid sequence homology of the different subtypes can vary by more than 
30-60% (Skehel, 2009). 
The primary reservoir for influenza A viruses is waterfowl. Three of the H 
subtypes (H1, H2, H3) and only two of the N subtypes (N1 and N2) can naturally 
infect humans as they attach specifically to the α-2,6-galactose linkages on 
human epithelial cells rather than to the α-2,3-galactose linkages found in avian 
intestinal cells. Other H and N subtypes can also be found in pigs, horses, bats 
and seals (Shors, 2013; Tong et al, 2013). 
Influenza A nomenclature is based on type, host, location, strain number and year 
of isolation for example for an avian strain of influenza isolated from a duck in 
2009 in Cardiff would be given the name A/mallard/Cardiff/1/09 (H5N2). Human 
viruses are named in a similar way but without host type for example 
A/Cardiff/1/09 (H1N1). 
Influenza B virus was isolated in 1940 (B/Lee/40) (Francis, 1940) and diverged 
into two lineages, Victoria and Yamagata in the 1980s (Rota et al, 1990) and is 
largely a human pathogen, although it has been reported to infect seals.  
Influenza C virus was isolated in 1947 but is not considered to be a major human 
pathogen (Joosting et al, 1968), with 96% of individuals developing antibodies 
against influenza C by early adulthood (Wright et al, 2013). 
1.2. Replication: 
The H proteins on the surface of influenza A viruses bind to sialic acid molecules 
on the surface of ciliated columnar epithelial cells that line the sinuses and airway 
of humans with α-2,6 linkages or the intestines of fowl with α-2,3 linkages (Cross 
et al, 2001; Shaw & Palese 2013; Shors, 2013). Cell entry is predominantly 
achieved by clathrin-mediated endocytosis, but can also occur via a clathrin–
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independent pathway (Lakadamyali et al, 2004; Shaw & Palese, 2013). The low 
pH of the endosome triggers cleavage of the H protein to expose the fusion 
peptide. The fusion peptide inserts itself into the membrane of the endosome 
fusing the virus and endosome membranes (Cross et al, 2001). H+ ions enter the 
virion, causing the release of the viral ribonucleoproteins (vRNPs), into the 
cytoplasm (Shaw & Palese, 2013; Shors, 2013).  
The vRNPs are transported to the nucleus of the host cell, by nuclear localisation 
signals on the NS1 (Whittaker, 2001, Shaw & Palese, 2013)). The polymerase 
proteins PB1 and PA use nucleotides from the host cell as a primer to start viral 
RNA transcription, by first making a positive sense copy (complementary RNA 
(cRNA)), which is then used to make viral RNA (vRNA) (Shaw & Palese, 2013). 
The new viral segments are transported to the cytoplasm and translated into virus 
proteins. The new viral proteins are transferred to the cell membrane, where 
virion assembly takes place. One copy of each of the viral genome segments must 
be in each virion for it to be infectious. Release from the host cell is aided by the 
binding of H to the sialic acid-containing receptors on the host cell membrane. N 
binds to and cleaves the sialic acid from its receptor and releases the virus from 
the host cell (White & Fenner, 1994, Wagner et al, 2008, Shors, 2013). 
 
Figure 2 - Influenza Replication Cycle (Shaw & Palese, 2013). Diagramatic 
representation of the replication of influenza virus inside a host cell. 
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1.3. Disease: 
Influenza A virus was first isolated from swine in 1930 (Shope, 1931) and from 
humans in 1933 (Smith et al, 1933). In 1947 the World Health Organization 
(WHO) set up an influenza surveillance programme to monitor global influenza 
activity (Zambon, 1999). 
Classical influenza symptoms occur suddenly after a relatively short incubation 
period of 1-2 days and include; headache, high fever (pyrexia) (100-103
o
F (37.8-
39.4
o
C) for 3 days), chills (rigors), weakness and lethargy (malaise), aching limbs 
and back (myalgia), a dry cough and sore throat (White & Fenner, 1994; Shors, 
2013; Wright et al, 2013). Individuals may also suffer with blocked or runny nose 
with discharge (rhinorrhoea) and painful watery eyes (Carrat et al, 2008). 
In uncomplicated influenza infections, symptoms usually resolve after 7 days but 
lethargy may last for a few weeks. The elderly can also present with lassitude, 
confusion and high fever without any respiratory symptoms (White & Fenner; 
1994, Shors, 2013; Wright et al, 2013).  
Secondary complications such as croup, ear infections, otitis media and secondary 
bacterial pneumonia, often caused by Streptococcus pneumoniae and 
Haemophilus influenza can be seen in high risk individuals such as children, the 
elderly, the immunocompromised and individuals with pre-existing medical 
conditions such as congestive heart failure and underlying conditions which affect 
the heart, lungs, liver, kidneys and the endocrine system (Shors, 2013; Wright et 
al, 2013).  
Approximately 600 deaths each year in the UK are due to complications of 
influenza infection, and this can increase to around 13,000 during an epidemic 
(NHS, 2013). 
1.4. Epidemiology: 
The influenza season usually occurs in the winter months in temperate climates 
and during the rainy seasons in tropical climates. There are usually one or two 
strains that circulate in a particular region at any given time of the year (Shors, 
2013). Localised epidemics occur due to the short incubation period of the 
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disease, and the high titre of viral shedding particularly in children (Carrat et al, 
2008; Wright et al, 2013). Outbreaks are commonly associated with closed and 
semi-closed communities such as schools, hospital wards and nursing homes 
(Shors, 2013). 
Due to the error prone nature of RNA polymerase activity the mutation rate of 
influenza is high at approximately 1.5 x 10
-5 
mutations per nucleotide per cycle. 
This is the equivalent of 2-3 amino acid changes in the H protein per year. This is 
known as antigenic drift and can occur in both influenza A and B viruses. When 
significant drift occurs in the extracellular H and N proteins this can give rise to a 
reduced immune response in the host leading to localised epidemics, even in 
populations with previous exposure to influenza A of similar sub-type or prior 
seasonal influenza vaccination (Hay et al, 2001; Shors, 2013; Zambon, 1999).  
Antigenic shift is a dramatic change in the genome of influenza, caused by the 
reassortment of the genome segments. Only influenza A viruses can undergo 
antigenic shift due to their zoonotic nature. The most common mechanism for 
antigenic shift occurs when a human and non-human (usually avian) virus infect a 
pig simultaneously, as the sialic acid receptors for both human and avian 
influenza A viruses exist in the upper respiratory tract of swine. This can lead to 
the expression of new H and N proteins on the cell surface and cause pandemics 
if the general population have not been previously exposed to the new virus (Hay 
et al, 2001; Shors, 2013; Zambon, 1999). The last three pandemics have been due 
to re-assorted viruses (Wright et al, 2013). 
1.5. Pandemics of the 20
th
 and 21
st
 Centuries: 
There have been four major influenza A pandemics in the last 100 years, H1N1 in 
1918 (“Spanish Flu”), H2N2 in 1957 (“Asian Flu”), H3N2 in 1968 (“Hong Kong 
Flu”) (Shors, 2013) and the recent H1N1pdm09 (“Swine Flu”) (Dawood et al, 
2009). H1N1 re-emerged in 1977 and has since co-circulated with H3N2 as 
seasonal influenza (Hay et al, 2001) before being displaced by the emerging 
H1N1pdm09 strain in 2009.  
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1.5.1. “Spanish Flu” - 1918-19: 
The origin of the H1N1 virus in 1918 is unknown but has been thought to be 
related to outbreaks of respiratory infections associated with high mortality and 
heliotrope cyanosis in Etaples, France, in 1916 and in Aldershot, UK in 1917 and 
an outbreak of influenza that led to pneumonia and death in young adults in 
Kansas, USA at the start of 1918 (Wright et al, 2013). 
The first wave of the disease was mild, but highly contagious and spread via the 
railway and troopships across America and into Europe. The disease was named 
the “Spanish Flu” due to the unrestricted media coverage about the disease from 
Spain. A second wave started in late August 1918 with a high mortality rate, and 
a final wave began late 1918-early 1919 with morbidity rates similar to the 
second wave (Wright et al, 2013).   
This pandemic was estimated to have killed 2.5% of infected individuals (the 
usual mortality rate for seasonal influenza is <0.1%), resulting in 20-50 million 
deaths worldwide (Shors, 2013, Wright et al, 2013). Influenza pandemics often 
cause a high mortality rate in children and young adults, and although the 
morbidity of the “Spanish Flu” was high in this age group the mortality rate was 
greatest in 15-35 year olds (Wright et al, 2013). This strain was closely related to 
the classic swine influenza virus and the sequences of the H and N proteins were 
related to an avian influenza virus that had not circulated in humans or pigs for 
many decades before the pandemic (Shors, 2013).  
1.5.2. “Asian Flu”- 1957-58: 
The “Asian Flu” first emerged in China in February 1957, and was isolated and 
identified as H2N2 in Japan, in May (Wright et al, 2013). It mainly infected 5-19 
year olds and led to 1-4 million deaths worldwide. It was caused by a 
reassortment of avian H, PB1 and N segments with human influenza genes 
(Shors, 2013; Wright et al, 2013). This virus displaced the previously circulating 
influenza a H1N1 to become the seasonal influenza A type. 
1.5.3. “Hong Kong Flu” - 1968: 
During 1968 the H2N2 influenza A virus was displaced by an emerging H3N2 
virus, which contained avian H and PB1 gene segments. The pathogenicity of this 
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virus was moderate compared to previous pandemics possibly as a consequence 
of residual antibodies to the N2 component in individuals exposed to the 
previously circulating H3N2 virus. As a result of this pandemic, an excess of 
33000 deaths were recorded in the USA, and a high attack rate (40%) was 
observed in 10-14 year olds (Wright et al, 2013). 
1.5.4. “Swine Flu” – 2009-10: 
In April 2009, 2 unrelated cases of an influenza-like illness were reported in 
California, following reports of a major respiratory disease outbreak in Mexico 
(Dawood et al, 2009; WHO, 2009b). The virus causing these illnesses was 
discovered to be a new emerging triple-re-assorted strain of influenza A H1N1 (a 
mix of human (PB1 gene of H3N2), swine (NP and NS) and American (PB2 and 
PA) and Eurasian (N and M) avian influenza A gene segments (Wright et al, 
2013)) which was genetically unrelated to the circulating human seasonal strain. 
The WHO announced a global pandemic on June 11, 2009. By the end of June 
2009 this strain of virus had caused 70893 confirmed cases of influenza and 311 
deaths worldwide (WHO 2009c). 
1.5.5. Other Emerging Influenza Strains – 1997-2013: 
In Hong Kong in the second half of 1997, 18 cases and 6 deaths of influenza 
caused by an avian strain of influenza A, H5N1 were reported. Until then there 
had never been a reported case of avian influenza that was fatal to humans. 
Unlike human adapted strains of influenza A direct human to human transmission 
was shown to be limited and as a consequence it was proven that for the first time 
an avian strain of influenza had jumped directly from bird to man without the 
intermediate swine host. This virus causes a severe influenza illness, and has been 
found in the stool and CSF of patients in addition to the respiratory organs 
demonstrating a more systemic infection. Due to the high mortality rate of 33% in 
1997 (it is now 59%) concerns were raised that this virus could lead to a 
pandemic of great proportions. To date there have been 615 cases of avian flu in 
humans resulting in 364 deaths, throughout Asia, Southeast Europe and Africa 
(WHO, 2010; Wright et al, 2013).  
 9 
 
A novel strain of “Avian Flu” has recently been identified as H7N9. The H7 
subtype is often found in poultry worldwide but this is the first time it has been 
reported in humans. Since its isolation from 3 patients in March 2013, H7N9 has 
infected 132 individuals leading to 32 deaths. Human-human transmission has not 
yet been verified (Gao et al, 2013; WHO, 2013).  
A triple-re-assorted H3N2 influenza A virus was identified in 2011, which 
included the M gene segment from the H1N1pdm09 strain and was antigenically 
distinct from seasonal influenza viruses (Lindstrom et al, 2012). 
1.6. Laboratory Diagnosis and Detection of Influenza: 
Clinical diagnosis of influenza can be difficult due to the similarity of symptoms 
to other respiratory infections and diseases. It is therefore preferable to have a 
laboratory diagnosis and confirmation of influenza or other respiratory infection 
so that appropriate action can be taken and where necessary effective treatment 
can be given to the patient.  
Nasopharyngeal aspirates (NPA) and throat swabs are the preferred sample type 
for the growth of influenza in cell culture. Classical isolation techniques favoured 
cell lines such as primary monkey kidney cells and madin-derby canine kidney 
(MDCK) cells. Cytopathic effects or changes in the morphology of the infected 
cells are rarely seen in influenza so a marker of infection test was routinely 
performed called haemadsorption. When erythrocytes are exposed to viral 
haemagglutinin, which is expressed on the cell surface of the infected host cell or 
cell culture system, they become bound to the infected cell via the sialic acid 
receptor on the cell surface of the red cell. This phenomenon can then be 
visualised by standard microscopy (Figure 3) (Shelokov et al, 1958; White & 
Fenner, 1994). 
 10 
 
 
Figure 3 – Haemadsorption. A photograph of red blood cells adhering to cell 
culture infected with influenza. Magnification unknown. 
(http://dc231.4shared.com/doc/1OJVQm4w/preview.html). 
A number of different viruses such as the parainfluenza viruses and mumps virus, 
also express haemagglutinin on the cell surface and so to confirm influenza 
infection a second confirmatory test was then performed, routinely using indirect 
or direct immunofluorescence, where a specific monoclonal antibody is tagged 
with a fluorophore and applied to the infected cell layer (Figure 4) (White & 
Fenner, 1994; Mims et al, 1999; PHW 2010; Shors, 2013).  
 
Figure 4 – Immunofluorescence. The staining of cells infected with influenza, using 
fluorescent labelled Anti-HA antibodies. Magnification unknown. 
(http://www.abcam.com/ha-tag-antibody-chip-grade-ab9110.html). 
The whole process from inoculation of the cell line to confirmation by 
immunofluorescence could take from 5 -14 days, more recently rapid culture 
Red blood cells.  Cell culture cells. 
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techniques were developed to allow detection of respiratory viruses in 1-2 days. 
These are based on the principal of shell vial cell culture, the most commonly 
used commercial shell vial system is R-mix (Microgen Bioproducts, Camberley, 
UK), which are a mixture of human adenocarcinoma cells-A549 and mink lung 
cells. The cell monolayer is grown at the bottom of the vial and the sample is 
centrifuged onto it to enhance the infectivity. After incubation the samples are 
fixed and stained by immunofluorescence to target up to 8 different respiratory 
viruses (Landry, 2011). 
More recently molecular based techniques have revolutionised the way influenza 
is diagnosed in the laboratory. The polymerase chain reaction (PCR) was first 
described by Kary Mullis in 1985 (Mullis & Faloona, 1987) and remains the basis 
for most routinely applied molecular assays. Although other molecular techniques 
have been described and applied for the detection of influenza viruses (Table 1). 
Table 1 - Molecular methods suitable for the detection of influenza viruses (adapted 
from Ellis & zambon, 2002). 
Method  Advantages  Disadvantages 
Hybridisation High specificity  
Flexible formats  
Inexpensive 
Sensitivity,  
Time-consuming 
PCR Sensitive and specific  
Allows further product analysis 
Qualitative, not usually 
quantitative 
Multiplex PCR Sensitive and specific  
Tests >1 target per assay  
Allows further product analysis  
Requires extensive 
optimisation to ensure no false 
negatives or primer 
competition 
May be limited by product 
PCR EIA Sensitive and specific High 
throughput  
Not limited by product size  
Can be multiplexed 
Does not allow further product 
analysis 
Requires additional 
evaluation/validation before 
use 
Real-Time PCR Sensitive and specific  
Rapid 
Can be quantitative 
Can be multiplexed 
Requires specialised 
equipment Product analysis not 
always feasible 
 
NASBA Sensitive and specific  
Can be quantitative 
 
Three enzymes used 
Time-consuming 
RNA product analysis less 
feasible 
 
The initial step for any molecular technique is to produce good quality nucleic 
acid from the starting sample. In 1990, Boom described a method where starting 
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clinical material was exposed to a chaotropic reagent (guanidinium thiocyanate) 
to simultaneously release nucleic acid from the cell and to inactivate nuclease 
enzymes thus preventing nucleic acid degradation. The nucleic acid was then 
bound to silica particles which could then be exposed to decreasing solutions of 
salt buffers to remove all contaminating material. The ‘pure’ nucleic acid could 
then be unbound from the silica by addition of a very low salt concentration of 
salt buffer or nuclease free water. This ‘Boom principal’ of nucleic acid 
extraction was later modified and adapted into various manual extraction methods 
and finally automated to allow rapid nucleic acid extraction with a higher 
throughput. 
To apply PCR for the detection of influenza virus having an RNA genome, a 
preliminary reverse transcription step is required to form a complimentary strand 
of DNA (cDNA) from the target viral RNA. Previously this was performed using 
a separate step often using random primers to form cDNA strands of all RNA 
present in the extracted nucleic acid. Specialised reverse transcription enzymes 
were available including avian myoblastomavirus (AMV) reverse transciptase. 
The resulting cDNA could then be used as the starting template for the PCR 
reaction (Ellis & Zambon, 2002). 
The PCR reaction itself is primer driven in that short complimentary DNA 
primers flanking the target region (often a highly conserved part of the genome) 
of interest are designed to initiate amplification. For influenza several targets are 
widely selected including the nucleoprotein and matrix genes. This allows for 
generic amplification of the genome of all known circulating types of influenza 
A. Sub-typing of influenza A requires the targeting of the external H gene and in 
some cases the N gene to differentiate the different types (Mahoney et al, 2011).  
Simplification of the methods and development of ‘all in one’ mastermixes 
containing the RT and PCR enzymes, the deoxynucleotide triphosphates (dNTPs) 
and salts have enabled this two-step process to become a single-tube process 
where the reverse transcription step and then amplification are performed one 
after the other without any extra manipulation. By adding in target specific 
labelled probes which anneal to the target amplicon as it is produced in the PCR 
reaction, the amplification process can now be monitored in real-time. Where 
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development and or validation of the primer and probe sets are performed by the 
testing laboratory these are commonly called in-house or homebrew assays 
(Mahoney et al, 2011).  
Commercially available molecular assays for influenza are now commonly 
available and are increasing in popularity. During 2008, 3 commercial real-time 
RT-PCR assays for the detection of influenza were authorised for use in the USA 
by the Food and Drug Administration (FDA) (Landry, 2011).  
Even more rapid diagnostics tools have since been developed and are called Point 
Of Care Tests (POCT). These tests are based on immuno-fluorescent or enzyme-
linked immuno-sorbent (ELISA) assays. They can give a result in 10-30 minutes 
and can distinguish between influenza A or B, but can have a false negativity rate 
of about 30% (Shors, 2013; Tayo et al, 2012). More POCT are being developed 
with the aim to increase their sensitivity and be able to distinguish between 
influenza subtypes. These include RT-PCR aspects and specialised equipment 
(likely immobile), which would increase the cost, and the subsequent turn-around 
time for a result would increase to 45-60 minutes (Tayo et al, 2012).  
1.7. Prevention: 
Vaccination remains the most effective method for prevention and control of the 
morbidity and mortality associated with influenza infection. In the UK, persons in 
high risk groups and healthcare workers are offered vaccination from September 
onwards in preparation for the forthcoming influenza season (Schuffham & West, 
2002).  
Inactivated influenza vaccines are routinely used in the UK during the seasonal 
influenza vaccine campaign. They can be derived from whole virus, split virus or 
purified surface antigen preparations (Pillay et al, 1998; Matthews, 2006). 
Seasonal influenza vaccines were first developed in the 1940s and were 
monovalent. Bivalent vaccines were introduced in the 1960s and trivalent 
vaccines were introduced in the 1970’s, and remain the vaccine composition of 
choice. They are composed of a currently circulating H1N1 and H3N2 strain of 
influenza A virus and one lineage of influenza B virus (Matthews, 2006). 
Quadrivalent vaccines are now approved for use in the USA, and include both 
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influenza B lineages (Neuzil & Victor, 2014). Live, attenuated influenza vaccines 
administered intranasally have more recently been introduced as part of the 
influenza vaccine campaign in healthy children in the UK (NHS, 2014). The 
composition of viruses used in the seasonal influenza vaccine is based upon the 
global surveillance of circulating strains. The data used to help with this decision 
is taken from; antigenic analysis of recently isolated viruses, epidemiological data 
and post vaccine serological studies (Shors, 2013). 
Vaccine efficacy varies from 70–80% in healthy young adults but is less effective 
in the elderly. Despite this, evidence shows that vaccines help to reduce the 
severity of the disease if they don’t manage to prevent infection (Donaldson and 
Donaldson, 2006).  
1.8. Treatment: 
Healthy individuals presenting with influenza are advised to stay at home and 
take analgesics (not aspirin due to the risk of Reyes syndrome in the young). 
However for high risk individuals and in complicated cases of influenza, antiviral 
agents such as the adamantanes and neuraminidase inhibitors may help to reduce 
the length and severity of the infection. 
1.8.1. Adamantanes: 
The first antivirals developed for the treatment of influenza were the 
adamantanes, Amantadine and Rimantadine. These drugs inhibit the action of the 
M2 ion channel in the virus envelope, preventing the pH reduction inside the 
virus to allow release of the RNPs. In higher concentrations, the adamantanes can 
also affect the acidity of the endosome and Golgi apparatus of the host cell, 
preventing the action of the M2 ion channels and activating H proteins too early 
in the replication cycle thus producing non-infectious progeny (Wingfield et al, 
1969; Hay et al, 1985; Whittaker, 2001). Adamantanes work most effectively 
when taken prophylactically and are effective against 50-90% of influenza A 
viruses (Douglas, 1990). However, the side effects associated with this class of 
antivirals are considerable and occur in around 30% of cases when given as 
prophylaxis, they include; insomnia, concentration difficulties, hallucinations, 
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seizures and other CNS related effects, renal dysfunction and gastrointestinal 
symptoms (Douglas, 1990; Shors, 2013).  
1.8.2. Neuraminidase Inhibitors: 
As mentioned previously N is important in the binding to and release from host 
cells. Due to this role it was targeted as a possible site for new antiviral drugs. 
This was first investigated by Edmond et al in 1966, but they were unable to 
identify any potent compounds. Newer techniques and greater awareness has 
allowed for rapid development in this field. 
Neuraminidase (N) cleaves N-acetyl neuraminic (Sialic) acid from α2-3 or α2-6 
linkages on the host cell, thus destroying the cell receptor and releasing the newly 
formed virus particle from the host cell (Colman, 2009). The catalytic site (Figure 
5) of neuraminidase has four invaginations accommodating the substituents at C2, 
C4, C5 and C6 on the Sialic acid (Varghese et al, 1992). The C2 carboxylase is 
bound in a twist boat formation to a cluster of 3 arginyl groups (R) at positions 
118, 292 and 371 on the N sequence. The C5 binds to a tryptophan residue (W), at 
position 178. A cluster of hydrogen bonds bind to the C6 glycerol group and the 
hydroxyl group at C4. The C8 and C9 hydroxyl groups are bound by hydrogen 
bonds to a Glutamic acid residue (E) at position 276. Another amino acid 
believed to be part of the catalytic reaction is a tyrosine (Y) residue at position 
406 (Colman, 2009). The above mentioned amino acids are believed to be 
conserved due to their importance in the catalytic reaction to enable viral release 
(Colman et al, 1983) and are supported by the substrate and framework residues 
E119, R156, W178, S179, D/N198, I222, E227 N294 and E425 (Yen et al, 2006). 
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Figure 5- The active site of neuraminidase (Yen et al, 2006). A diagramatic 
representation of the active site of neuraminidase when it binds to sialic acid.  
The product from the neuraminidase-sialic acid reaction produces α sialic acid or 
Neu5Ac (Figure 6). This product is the basis for the design of the modern 
neuraminidase inhibitors (NAIs), developed by rational, computer assisted drug 
design software such as GRID (von Itzstein et al, 1993). The action of the NAI’s 
reduces the number of virus particles able to be released from the host cell to 
infect new cells (McKimm-Breschkin et al, 2003; Moscona, 2005). 
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Figure 6 – Sialic acid (Das et al, 2010). The molecular structure of sialic acid.  
 
1.8.2.1. Zanamivir: 
Zanamivir (4-guanidino-Neu5Ac2en) (GG167) (Figure 7), commercially known 
as Relenza
TM
 (GlaxoSmithKline, London, UK), was the first neuraminidase 
inhibitor to be developed. It contains a guanidinyl group at C4 (highlighted in 
Figure 7, the green circle) instead of the hydroxyl group of sialic acid (von 
Itzstein et al, 1993). This small structural change allows the inhibitor to bind in 
the active site and due to the lateral binding of the terminal nitrogen’s of the 
guanidinyl group to E119 and E227 promotes better affinity (von Itzstein et al, 
1993; Colman, 1994). Zanamivir is given by inhaler and has been shown to be 
approximately 1000 times more effective than amantadine and is effective against 
influenza A and B viruses (von Itzstein et al, 1993).  
C4 
C6 
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Figure 7 – Zanamivir (Das et al 2010). The molecular structure of zanamivir.  
1.8.2.2. Oseltamivir: 
Oseltamivir (GS 4104) (Figure 8), commercially known as Tamiflu
TM 
(Roche, 
Basel, Switzerland), was developed in 1998 and was the first orally bioavailable 
NAI (Li et al, 1998). Oseltamivir has an amino group at C4 (Figure 8 - green 
circle) and a 3-pentyloxy group instead of the glycerol group at C6 (Figure 8 - red 
circle). Oseltamivir also promotes higher binding affinity than sialic acid. To 
allow oseltamivir to bind to the active site in the neuraminidase, the binding site 
must create a pocket for the large side chain of oseltamivir. This is achieved by 
the rotation of E276 which then binds to R224 (Moscona, 2005). 
 
Figure 8 – Oseltamivir (Das et al 2010). Molecular structure of oseltamivir. 
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The similar modes of binding for oseltamivir (green) and zanamivir (yellow) to 
the sialic acid substrate (grey) can be seen in figure 9.  
 
Figure 9 – Binding of neuraminidase inhibitors with neuraminidase (Das et al 2010). 
Diagramatic representation of the similar modes of binding for oseltamivir, 
zanamivir and sialic acid. 
 
1.8.2.3. Use of NAIs: 
NAI’s were licensed and introduced between 1999 and 2002 for clinical use 
worldwide (McKimm-Breschkin et al, 2003). 
For NAIs to be most affective they should be administered within 48 hours of 
symptom onset. As the drug itself is viral static preventing virion release, the drug 
needs to be given twice daily for a minimum of 5 days to allow for replication to 
be halted. The host immune response will then have time to develop antibodies to 
neutralise the virus and clear the infected cells. 
In the UK, prescribing of NAIs is governed by the National Institute for Health 
and Care Excellence (NICE) who provide guidelines for the use of antivirals for 
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the treatment of influenza (TA168) (NICE, 2009). Prescribing is only 
recommended when influenza is circulating in the community and only given to 
patient groups who are at significant risk of severe infection, essentially all those 
groups who are entitled to receive annual seasonal influenza vaccination. 
Prophylaxis is only recommended in high-risk groups exposed to influenza and in 
outbreak management.   
1.9. Resistance: 
Resistance to the adamantanes was first described in H3N2 viruses during the 
1970’s and is associated with a point mutation at position 31 of the M2 gene 
which changes the amino acid residue from serine (S) to asparagine (N). This 
prevents binding of the drug to the M2 ion channel (Belshe et al, 1988). By the 
2005-2006 influenza season in the US, 96.4% of H3N2 viruses tested were 
resistant to the adamantanes and the FDA no longer recommended the use of this 
class of antivirals for the treatment of H3N2 viruses. During this same season 
15.5% of H1N1 viruses tested worldwide were also resistant to the adamantanes 
(Deyde et al, 2007).  
The susceptibility of influenza to NAIs is usually measured as the drug 
concentration inhibiting neuraminidase activity by 50% (IC50). NAI resistance is 
defined as “a significantly raised IC50 value coupled with a characterised 
mutation in the neuraminidase gene” (Lackenby et al, 2008b).  
Mutations that were noted to confer high level resistance or reduced NAI 
susceptibility from challenge studies and clinical isolates were H274Y (a point 
mutation at position 274 changing the amino acid code CAT for histidine (H) to 
TAT for tyrosine (Y)) in N1 viruses (Gubareva et al, 2001a), R292K (AGA for 
Arginine to AAA for Lysine) and to a lesser extent E119V (GAA for Glutamic 
acid to GTA for Valine) and N294S (AAC for Asparagine to AGC for Serine) in 
N2 viruses, (Gubareva et al, 1996; McKimm-Breschkin et al, 2003; Kiso et al, 
2004). The most observed point mutation was at position D151 (Aspartic acid). 
This occurred in both N1 and N2 viruses and caused various amino acid changes 
(McKimm-Breschkin et al, 2003). At the time of these studies, it was 
hypothesised that these mutations would result in ‘less-fit’ viruses in that they 
would demonstrate poor growth and be poorly transmitted (Gubareva et al, 1997, 
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Tai et al, 1998, Covington et al, 2000, Wang et al, 2000, Gubareva et al, 2001a, 
Whitley et al, 2001, Carr et al, 2002, McKimm-Breschkin et al, 2003).  
These preliminary studies demonstrated largely that all clinical isolates were 
susceptible to oseltamivir and zanamivir and there was no evidence for naturally 
occurring resistance. It was also shown that N1 viruses were more susceptible to 
zanamivir, and N2 viruses were more susceptible to oseltamivir (McKimm-
Breschkin et al, 2003; Ferraris et al, 2005).  
The Neuraminidase Inhibitor Susceptibility Network (NISN) was set up to 
monitor the development of resistance to NAIs after their introduction. 
Surveillance during the first 3 years of NAI use showed low levels of viruses with 
reduced susceptibility, 0.22% in the 1999-2000 season and 0.41% in the 2001-
2002 season. The resistant viruses that were found showed a >10-fold decrease in 
their susceptibility to oseltamivir and in some cases to zanamivir (Monto et al, 
2006). The amount of global resistance remained at a similar level over the next 
few years, 0% for the 2004-2005 season; 0.4% for the 2005-2006 season and 
0.6% for the 2006-2007 season. A rise in resistance to oseltamivir was observed 
in H1N1 viruses from the start of the 2007-2008 season associated with the 
H274Y mutation (Sheu et al, 2008) with 14% of confirmed cases showing 
resistance in Europe (Lackenby et al, 2008a). Different geographical locations 
showed a range of 0-70% for H1N1 resistance to oseltamivir during the 2007-
2008 season (Lackenby et al, 2008a; Deyde et al, 2009b) but by 2008-2009, 96% 
of all seasonal H1N1 viruses were demonstrated to have the H274Y mutation 
(NISN, 2010).  
1.10. Detection of NAI Resistance: 
Phenotypic drug susceptibility tests such as neuraminidase inhibition assays 
(NIA) and plaque reduction assays (PRA) are routinely used to monitor for the 
emergence of drug resistance. Tobita et al first described the growth of influenza 
in plaques in 1975. This method was modified by Hayden et al (1980) to develop 
drug susceptibility testing for Adamantanes. Influenza isolates are inoculated into 
and grown in cell culture. Once suspensions of 50-150 plague forming units 
(PFU) are present they are added to monolayers of MDCK cells grown in culture 
dishes and incubated for 60mins at 36
o
C. An agarose overlay containing essential 
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medium and the appropriate dilution of the test drug is added and incubated for 
36-48 hours at 36
o
C. Plaques are then stained and compared to a control 
containing no drug (Hayden et al, 1980). Variations and modifications of these 
first assays have been performed to allow the phenotypic testing of neuraminidase 
inhibitors (Buxton et al, 2000; Gubareva et al, 2002; McSharry et al, 2004; Miller 
et al, 2006). 
Genetic sequencing of the neuraminidase gene can be undertaken to determine 
the presence of mutations that commonly confer resistance to neuraminidase 
inhibitors predominantly using Sanger based sequencing methods (Sanger et al., 
1977). Sanger sequencing is now largely performed on automated systems, 
following an initial PCR of the target region. These are divided into 2 types, gel 
based systems which separate fluorescently labelled DNA fragments by 
electrophoresis through a denaturing polyacrylamide gel and capillary based 
systems which electrophorese the samples through an array or single capillary 
which is filled with polyacrylamide or other specially developed polymers 
(Graham and Hill, 2001).  
1.10.1. Pyrosequencing: 
Pyrosequencing was developed by Ronaghi et al in 1996, this method was based 
on the enzymatic luminometric inorganic pyrophosphate (PPi) detection assay 
(ELIDA) developed by Nyren in 1987. 
Before the pyrosequencing reactions can take place, the target sequence needs to 
be amplified using a primer set which has one primer biotinylated. The amplified 
product is then mixed with streptavidin beads. The biotin label will enable the 
binding of the double stranded target nucleic acid to the beads (figure 10a). The 
beads are captured onto filter probes using a vacuum (figure 10b). The double 
stranded nucleic acid is then washed and denatured to leave the biotin labelled 
nucleic acid strand attached to the beads (figure 10c). A sequencing primer is then 
annealed to the single stranded biotin labelled nucleic acid (figure 10d). 
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Figure 10 - Representation of the stages of DNA preparation before addition to the pyroseqencer (Qiagen, 2014).                                        
a) Binding of biotinylated strands to streptavidin beads. b) Vacuum collection of streptavidin beads. c) Washing of beads to create single 
stranded DNA. d) Annealing of sequencing primer to single stranded DNA.  
a) b)
) 
 a) 
c) d) 
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Pyrosequencing is a rapid, real time sequencing method involving a cascade of 
enzymatic reactions (Figure 11).  
The sequencing primer and single stranded DNA target from the preparation 
stage is mixed with the substrates luciferin and adenosine 5’ phosphosulfase 
(APS), and the enzymes apyrase, luciferase, adenosine triphosphate (ATP) 
sulfurylase and DNA polymerase. dNTP’s are added to the reaction one at a time. 
If the dNTP is complementary to the base in the target it is incorporated into the 
DNA strand by the action of DNA polymerase. In response to each addition of 
dNTP to the DNA strand, pyrophosphate (PPi) is released. PPi is then converted 
by ATP sulfurylase into ATP in the presence of APS. ATP catalyses luciferase, 
leading to the conversion of luciferin to oxyluciferin, and the production of light. 
The amount of light produced is measured by a charge-coupled device (CCD) 
camera and is produced as a peak on a graph known as a pyrogram
™
 (Ronaghi et 
al, 1996; Ahmadin et al, 2000). 
 
Figure 11- The pyrosequencing cascade (Adapted from Ahmadin et al, 2006). 
Schematic diagram of the enzyme cascade which occurs to produce a pyrogram. 
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A pyrosequencing assay was developed in 2005 for the detection of resistance to 
the adamantanes (Bright et al, 2005). This lead to the development of a similar 
assay for the detection of NAI resistance, once increased resistance to oseltamivir 
in H1N1 viruses was observed. The first pyrosequencing assays for NAI 
resistance have been concentrating on detecting only the H274Y mutation in 
H1N1 viruses (Duwe & Schweiger, 2008; Deyde et al, 2009a; Bolotin et al, 2009; 
NISN, 2010).  
More recently Deyde et al (2009b) described pyrosequencing assays to detect all 
mutations known to confer reduced susceptibility to the NAIs in seasonal 
influenza A viruses (Deyde et al 2009b). 
1.11. Aims and Objectives: 
Due to the increased emergence of influenza viruses resistant to the 
neuraminidase inhibitors and the development of new rapid sequencing assays it 
was decided that these assays could be used as a routine diagnostic test. 
The primary aims of this study were: 
 to develop and optimise assays based on published methods for use as a 
series of rapid, routine diagnostic assays to determine the presence of 
mutations within the neuraminidase gene that confer resistance to 
oseltamivir and zanamivir in influenza A. 
 to optimise the assays so that results could be achieved rapidly directly 
from clinical samples and not from cultured virus. 
This would include assays for: 
 The H274Y mutation in H1N1 viruses.  
 The mutations at position D151 in H1N1 viruses.  
 The E119V, D151 and R292/N294 mutations in H3N2 viruses.  
 The H274Y mutation in H1N1pdm09 viruses.  
Once assay optimisation was achieved, a clinical validation was performed on a 
series of clinical samples received during the 2008-2009, 2009-2010 and 2010-
2011 seasons. 
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2. Materials and Methods: 
2.1. Control Material: 
Stock influenza A reference strains, A/Moscow/10/99 (H3N2) and A/New 
Caledonia/20/99 (H1N1) were inoculated into PLC cells (human liver hepatoma 
cells, Alexander cell line). Briefly; the reference strains were retrieved from long 
term storage in liquid nitrogen and thawed at 37
o
C. 100µl of each reference strain 
was added to 2 vials containing PLC cells and growth medium. The inoculated 
cell vials were incubated in a sloped (approximately 80
o
) stationary position to 
ensure inoculation of the cell line, at 37
o
C for 6 days. The 2ml of media was 
changed every alternate day to maintain conditions for growth.  
Haemadsorption was undertaken at 6 days to confirm the presence of influenza A 
virus (see Shelokov et al, 1958) using human O type red cells, supplied by the 
Blood Transfusion Services at University Hospital Wales (UHW), Cardiff. 
Briefly; approximately 15ml of human O type red blood cells were centrifuged at 
1500rpm for 3 minutes. The supernatant was removed and the cells were re-
suspended in sterile phosphate buffered saline (PBS). This stage was repeated 2 
more times. After washing the supernatant was removed and discarded. 75µl of 
the packed red cells were added to 20ml of PLC maintenance media. The media 
from the influenza culture tubes was removed and saved. 0.5ml of the PLC media 
diluted O cells was added to the influenza culture tube. The tube was incubated at 
4
o
C in a sloped (approximately 80
o
), stationary position for 20-30 minutes. The 
tube was then examined for the presence of haemadsorption using a light 
microscope at approximately 200x magnification.  The infected cells were 
harvested to be used in the optimisation of the pyrosequencing assays. Briefly; 
the cell vials are scraped using a pastette to remove the cells from the vial. The 
cells are then suspended in maintenance media and frozen at -80
o
C. One drop of 
the harvested cells was used to perform direct immunofluorescence to confirm the 
presence of influenza A. Briefly; a drop of suspended cells was placed into a well 
on a glass slide and allowed to dry on a heat plate. The slide was fixed in acetone 
for 2-5 minutes. Excess acetone was allowed to evaporate before the addition of 
15µl of influenza monoclonal antibody. The slide was incubated in a moist box 
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for 15 minutes at 37
o
C. The slide was rinsed in a steady stream of PBS and 
allowed to dry at 37
o
C. Mounting fluid and a cover slip was applied before 
examination using an UV microscope. 
The control material was also tested using the RT-PCR assays for influenza 
detection and the subtyping assay (see sections 2.3 and 2.4) to confirm influenza 
A and the subtype of each strain used and to record their crossing thresholds 
(which was taken as a semi quantitative measure of material concentration).  
2.2. Clinical Isolates: 
Clinical samples including upper and lower respiratory samples (nose and throat 
swabs and nasopharyngeal aspirates and bronchial alveolar lavages) received for 
routine diagnostic testing by molecular techniques in the PHW Microbiology 
Cardiff, Molecular Diagnostics Unit during the 2008-2009, 2009-2010 and 2010-
2011 seasons which tested positive for influenza A virus were selected and 
anonymised for this study.  
2.3. Nucleic Acid Extraction from Control Material and Clinical 
Samples: 
Briefly, 200µl of control material, liquid sample or the dry respiratory swab was 
added to 0.9ml lysis buffer (bioMérieux, France), 200µl was then transferred to 
2ml lysis buffer for total nucleic acid extraction using the NucliSENS
®
 
EasyMAG
®
 (bioMérieux, France) automated extraction system, which is based 
on the Boom nucleic acid procedure as described previously. The purified nucleic 
acid was eluted into a volume of 60µl. The nucleic acid was stored at -80°C until 
processing. 
2.4. Generic Influenza A Detection by RT-PCR: 
During the course of this project a new in-house influenza A RT-PCR assay was 
introduced for the ABI Fast 7500 (Applied Biosystems
®
, Life Technologies
™
, 
California, USA), which was optimised from the protocol described by the 
Centers for Disease Control and Prevention (CDC) in 2009 utilising the TaqMan
®
 
Fast Virus 1-Step Master Mix (Applied Biosystems
®
, Life Technologies
™
, 
California, USA).  
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The assay was performed by adding 5µl of eluate to 20µl of RT-PCR mastermix 
containing; 62.5µl TaqMan® Fast Virus 1-Step master mix, primers at a final 
concentration of 0.8µM of each primer and a final concentration of 0.4µM of 
probe and 124µl RNAse free water (Ambion
®
, Life Technologies
™
, California, 
USA) (these values are for 10 reactions). Amplification was performed on the 
ABI Fast 7500 using the following amplification parameters 50
o
C for 5 minutes, 
95
o
C for 20 minutes and 40 cycles of 95
o
C for 3 seconds and 60
o
C for 30 
seconds.  
All samples and control material were tested by the new protocol to verify the 
previous results and to record the crossing threshold (CT) values of each sample. 
This assay is not quantitative, however the CT value can be used as an indicator 
as to the amount of virus present. A low CT value (e.g. 20) can mean the presence 
of a high number of virus in the sample, whereas a high value (e.g. 39) is 
suggestive of a low number of virus present or a poorly taken or stored sample. 
Sub-typing of influenza A positive samples was achieved using an assay based on 
those described by the health protection agency (HPA, now Public Health 
England, PHE), specifically targeting the H3 and H1 genes and optimised to use 
the same reagents and cycling conditions as the generic assay above.  
 
 
 
 
 
 
 
 
Table 2 – Primers and probes used for the identification and subtyping of influenza 
in clinical isolates using the ABI 7500 Fast. 
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Influenza 
Primers 
Sequence name Sequence 
Generic 
influenza A  
Forward Primer 5’ GACCRATCCTGTCACCTCTGAC 
Reverse Primer 5’ AGGGCATTYTGGACAAAKCGTCTA 
Probe 5’ 6-FAM-TCGCTCACTGGGCACG-MGB 
H1 subtyping  Forward Primer 5’ GGAATAGCCCCCCTACAATTG 
Reverse Primer 5’ AATTCGCATTCTGGGTTTCCTA 
Probe 5’ VIC-CGTTGCCGGATGGA-MGB 
H3 subtyping Forward Primer 5’ CCTTTTTGTTGAACGCAGCAA 
Reverse Primer 5’ CGGATGAGGCAACTAGTGACCTA 
Probe 5’ 6-FAM-CCTACAGCAACTGTTACC-MGB 
H1 pdm09 Forward Primer 5’ TTACCAGATTTTGGCGATCTAYT 
Reverse Primer 5’ CCAGGGAGACTASCARTACCA 
Probe 5’ 6-FAM-ACWGTCGCCAGTTC-MGB 
 
All assays used in clinical diagnostic laboratories are subjected to routine assay 
checks called proficiency panels. These panels check and ensure that all the 
laboratories across the country are detecting the correct results and that there are 
no faults or discrepancies in the assays. The PHW Microbiology Laboratories 
subscribe to 2 schemes, the National External Quality Assurance Scheme 
(NEQAS) and the Quality Control of Molecular Diagnostics Scheme (QCMD). 
The PHE also send out proficiency panels for the molecular detection of influenza 
during the respiratory season.  
The QCMD and PHE proficiency panels for 2010 were tested by the above 
methods and also through the H1N1pdm09 pyrosequencing assay as a method of 
validation. 
2.5. Amplification Primer Selection and Optimisation: 
Primers were selected to allow the amplification of targeted regions of the 
neuraminidase gene segment which include the point mutations mentioned 
previously. 
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2.5.1. Amplification Primer Selection: 
Amplification primers from several publications were selected for the study 
including H274Y and D151 point mutations in N1 viruses and E119V, D151 and 
R292/4 point mutations in N2 viruses described by Deyde et al (2009b). In 
addition, primers described by the HPA and those described by the WHO for the 
H274Y mutation in H1N1pdm09 viruses (WHO, 2009a). These primer sets allow 
the amplification of biotinylated DNA fragments of the neuraminidase gene 
segment. The annealing sites for the various primers were mapped to the 
neuraminidase gene sequences of the control influenza viruses and recently 
circulating clinical strains (see appendix I & II). 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3 – Amplification primers. 
Influenza 
Mutation 
Sequence 
name 
Sequence 
H1N1 H274Y HuH1N1- 274- 5’-AGATCGAGAAGGGGAAGGTTACTA-3’ 
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113bp F770 
HuH1N1- 274-
R882-biot 
5’-GTCYCTGCATACACACATCACT-3’ 
H1N1 D151 
117bp 
HuH1N1-151-
F425 
5’-ACAAACATTCAAATGGRACCG-3’ 
HuH1N1-151-
R521-biot 
5’-CTGACCATGCAACTGATTCAA-3’ 
H3N2 E119V 
584bp 
HuH3N2-F333-
biot 
5’-TGGGGACATCTGGGTGACA-3’ 
HuH3N2-R914 5’-ATATCTACTATGGGCCTATTGGA-3’ 
H3N2 D151 
145bp 
 
HuH3N2-F423 5’-CAACGTGCATTCAAATGACAC-3’ 
HuH3N2-R567-
biot 
5’-CCAYGCTTTYCCATCRTG-3’ 
H3N2 
R292/N294 
584bp 
HuH3N2-F333-
biot 
5’-TGGGGACATCTGGGTGACA-3’ 
HuH3N2-R914 5’-ATATCTACTATGGGCCTATTGGA-3’ 
H1N1 H274Y 
(HPA) 
301bp 
H1N1 PCR3 
 Forward 
5’-GGAGCCGTGGCTGTACTAAAATA-3’ 
H1N1 PCR3 
 Reverse-biot 
5’-CCACGTTTTGATTAAAAGACACC-3’ 
H1N1pdm09 
H274Y 
494bp 
Uni-sw-N1-B-
F780 
5’-GGGGAAGATTGTYAAATCAGTYGA-3’ 
Uni-sw-N1-B-
R1273-biot 
5’ CWACCCAGAARCAAGGYCTTATG-3’ 
 
2.5.2. Amplification Primer Optimisation: 
All of the primers selected for the study were compared to consensus sequences 
of current circulating influenza A strains (see appendix). Briefly, N1 and N2 
sequences were downloaded from Genbank and aligned using the online version 
of ClustalW http://www.ebi.ac.uk/Tools/msa/clustalw2/. The alignment of the 
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reverse E119V primer showed that some of the more recent circulating strains of 
H3N2 possessed a base change, C instead of A, in the middle of the binding site 
for the primer. Therefore a new primer was designed with the degeneracy K:  
5’-ATATCTACKATGGGCCTATTGG-3’. 
All primers used in the study were sourced from Eurogentec (Belgium).  
2.5.3. Annealing Temperatures: 
To further optimise the assay the annealing temperatures were calculated to 
ensure the correct PCR conditions were used for the primers that were utilised.  
The Basic Melting Temperature (Tm) for sequences can be calculated 
approximately using the following calculation: 
Tm= (wA+xT) * 2 + (yG+zC) * 4  
where w,x,y,z represents the number of the bases A,T,G,C in the sequence, 
respectively.  
 
 
 
 
 
 
Table 4 - Annealing temperatures for the primers used for amplification. 
Influenza 
Mutation 
Sequence name Tm 
H1N1 H274Y HuH1N1- 274-
F770 
5’-AGATCGAGAAGGGGAAGGTTACTA-3’ 
=72 
HuH1N1- 274-
R882-biot 
5’-GTCYCTGCATACACACATCACT-3’ 
=64-66  
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H1N1 D151 
 
HuH1N1-151-
F425 
5’-ACAAACATTCAAATGGRACCG-3’ 
=60-62 
HuH1N1-151-
R521-biot 
5’-CTGACCATGCAACTGATTCAA-3’ 
=60 
H3N2 E119V HuH3N2-F333-
biot 
5’-TGGGGACATCTGGGTGACA-3 
=58’ 
HuH3N2-R914 5’-ATATCTACTATGGGCCTATTGGA-3’ 
=64 
H3N2 D151 
 
 
HuH3N2-F423 5’-CAACGTGCATTCAAATGACAC-3 
=60 
HuH3N2-R567-
biot 
5’-CCAYGCTTTYCCATCRTG-3’ 
=50-54 
H3N2 
R292/N294 
HuH3N2-F333-
biot 
5’-TGGGGACATCTGGGTGACA-3 
=58’ 
HuH3N2-R914 5’-ATATCTACTATGGGCCTATTGGA-3’ 
=64 
 
The annealing temperature stated in the amplification reagent kit protocols was 
60
o
C. This temperature is optimal for the majority of the primer sets but could 
possibly be too high for the N2 D151 primers. Therefore the annealing 
temperature for the amplification of the N2 D151 DNA fragment was altered to 
55
o
C to create better amplification conditions for this target.  
2.5.4. Gel Electrophoresis: 
Gel electrophoresis was performed on a small proportion of the N2 amplicons to 
check the size (584bp for the E119V and R292/N294 and 145bp for the D151) 
and quality of the amplified product.  
A 2% agarose gel was made and loaded with 5µl of DNA ladder or product. The 
DNA was electrophoretically separated with a constant voltage of 90 Volts for 
45-60 minutes.  
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2.6. Amplification Optimisation: 
2.6.1. Superscript III RT/Platinum Amplification: 
The Deyde study (2009b) recommended the use of Superscript III RT/Platinum 
reagent kit (Invitrogen
™
, Life Technologies
™
, California, USA).  
Amplification was undertaken using the following reaction master mix: 1µl 
superscript enzyme, 25µl 2x reaction mix, 1µl of each 20µM primer (final 
concentration of 0.4µM), 17µl of RNAse free water and 5µl of template. 
Amplification was performed on a Veriti thermocycler (Applied Biosystems
®
, 
Life Technologies
™
, California, USA) using the cycling parameters: 50
o
C for 15 
minutes, 95
o
C for 2 minutes, 40 cycles of 95
o
C for 15 seconds and 60
o
C for 30 
seconds and then held at 4
o
C.  
2.6.2. Superscript III HiFi Amplification: 
To try to improve the quality of the amplicon used for sequencing, a high fidelity 
enzyme based kit was selected for evaluation, this was the Superscript III HiFi 
amplification reagent kit (Invitrogen
™
, Life Technologies
™
, California, USA). 
Amplification was undertaken using the same reaction mastermix composition as 
for the Superscript III RT/platinum reagent kit. Amplification was performed on a 
Veriti thermocycler using the cycling parameters: 55
o
C for 30 minutes, 94
o
C for 2 
minutes, 45 cycles of; 94
o
C for 15 seconds, 60
o
C for 30 seconds and 68
o
C for 30 
seconds and held at 4
o
C. The D151 N2 target was amplified using slightly 
different amplification parameters: 55
o
C for 30 minutes, 94
o
C for 2 minutes, 45 
cycles of; 94
o
C for 15 seconds, 55
o
C for 30 seconds and 68
o
C for 30 seconds and 
held at 4
o
C. 
2.6.2.1. Further Optimisation: 
Further optimisation of the N2 assays was undertaken by simply increasing the 
template DNA from 5µl to 10µl and finally to 15µl and decreasing the water 
within the mastermix. 
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2.6.3. Qiagen One-Step RT-PCR Amplification: 
During the course of this study, Qiagen (Limburg, The Netherlands) developed 
amplification reagents specifically designed for the Pyrosequencer.  
Amplification was performed using One-Step RT-PCR reagents (Qiagen, 
Limburg, The Netherlands).  
Briefly amplification was undertaken as follows: 5µl of One step RT-PCR Buffer 
5x, 1µl of each 20µM primer (0.8µM final concentration), 1µl of dNTP mix, 1µl 
of One step RT-PCR Enzyme mix, 11µl of RNAse free water, and 5µl of 
template. Amplification was performed on a Veriti thermocycler using the 
cycling parameters: 50
o
C for 30 minutes, 95
o
C for 15 minutes, 45 cycles of: 94
o
C 
for 30 seconds, 60
o
C for 30 seconds, 72
o
C for 30 seconds; 72
o
C for 10 minutes 
and held at 4
o
C. 
Amplification using the One-step RT-PCR reagents was further optimised by 
increasing the amount of eluate added to 10µl and reducing the water to 6µl. 
This protocol was also used for the detection of the H274Y mutation in 
H1N1pdm09 viruses. 
2.7. Pyrosequencer: 
Pyrosequencing was performed on the PyroMark Q96 ID (Qiagen, Limburg, The 
Netherlands), using the PyroMark Q96 ID Gold Reagents (Qiagen, Limburg, The 
Netherlands), which included lyophilised Enzyme and Substrate, which were 
reconstituted with RNAse free molecular grade water (Sigma, Missouri, USA) on 
day of use and dNTPs. The denaturation solution (sodium hydroxide), wash 
buffer, annealing buffer and binding buffer were specific for use with the 
PyroMark Q96 ID and supplied by Qiagen (Limburg, The Netherlands). The 
streptavidin sepharose beads were supplied by GE Healthcare Life Sciences 
(UK). All RNAse free Molecular Grade Water was supplied by Sigma (Missouri, 
USA) and Stock solution of 70% Ethanol was made with Absolute Ethanol 
(Fisher Scientific, Massachusetts, USA) and RNAse free molecular grade water. 
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2.7.1. Setting up an Assay on the Pyromark ID Software: 
The PyroMark
 
ID software was used to set up a single nucleotide polymorphism 
(SNP) run or a general sequencing assay (SQA). 
A run name (eg: H1N1 run 1 date) and the parameters stated on the reagent 
cartridge were selected in the General Tab. The reagent cartridge holds the 
Substrate, Enzymes and separate nucleotides for the assays (See Figure 12): 
 G  
C  T 
S A E 
Figure 12 - Diagramatic representation of the pyrosequencing cartridge layout. 
The reagent cartridge used for each run has a specific set of pressure, time and 
temperature parameters for the machine to adhere to. 
The volumes required for the reagent cartridge are calculated based on the 
number of times each nucleotide appears in the dispensation order and the total 
number of sequencing reactions. A simplex single nucleotide polymorphism 
(SNP) entry was programmed on the PyroMark
 
ID software for each point 
mutation. The entry includes the target sequence and the position where the point 
mutation occurs. From this the software calculates the best dispensation order for 
the nucleotides.  
A general sequencing assay (SQA) was also performed for some of the mutations 
to allow for determination of other changes at the same position. This requires a 
user defined dispensation order and TCGACTGA was selected based on the most 
commonly used order for sequencing. Rather than identify the SNPs the 
sequencing assay required user interpretation.  
The wells to be used for the assay were selected on the plate map and activated. 
The assay type (eg: H274Y) to be run and the sample numbers were selected and 
placed on the plate map. The reagent volumes were noted and the assay was then 
saved until required to be run. 
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2.7.2. Immobilisation of PCR Product by Streptavidin Sepharose HP Beads: 
Pyrosequencing reagents were used at room temperature. The streptavidin 
sepharose HP beads were homogenised by shaking the solution. An 
immobilisation solution was made up as follows: 3µl of streptavidin sepharose 
HP beads, 40µl Binding buffer and 17µl of RNAse free molecular grade water. 
60µl of immobilisation solution was added to the wells of a PCR plate 
corresponding to the plate map on the PyroMark
 
ID software. 20µl of PCR 
product was added to the immobilisation solution in the same order as stated on 
the plate map on the PyroMark
 
ID software. The plate was sealed with a plate 
sealer and placed on a shaker for 5-10 minutes at 1400rpm to allow the 
biotinylated DNA amplicon to bind to the streptavidin beads. 
2.7.3. Sequencing Primers: 
The sequencing primers matching the assays described previously for the H274Y 
and D151 point mutations in N1 viruses and E119V, D151 and R292/4 point 
mutations in N2 viruses by Deyde et al (2009b), the HPA primer for the H1N1 
H274Y mutation and the WHO primer for the H274Y mutation in H1N1pdm09 
viruses (WHO, 2009a) were used in the study. These primers bind to the 
biotinylated single stranded DNA immobilized by the sepharose beads and allow 
the binding of dNTPs to produce the DNA sequence. 
 
 
 
Table 5 – Pyrosequencing Primers. 
Influenza 
Mutation 
Sequence 
name 
Sequence 
H1N1 H274Y HuH1N1-274-
F807-seq 
5’-AAATGCACCCAAT-3’ 
H1N1 D151 
 
HuH1N1-151-
F425-seq 
5’-ACAAACATTCAAATGGRACCG-3’ 
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H1N1 H274Y 
HPA 
HuH1N1-274-
F807-seq 
5’-AGTTGAATGCACCCAAT-3’ 
H3N2 E119V HuH3N2-
R377-seq 
5’-GGATCGCATGACACATA-3’ 
H3N2 D151 HuH3N2-
F423-seq 
5’-CAACGTGCATTCAAATGACAC-3’ 
H3N2 
R292/N294 
HuH3N2- 
R905-seq 
5’-ATGGGCCTATTGCAGCC-3’ 
H1N1pdm09 
H274Y 
Uni-sw-N1-B-
F804-seq 
5’GYTGAATGCMCCTAATT-3’ 
2.7.4. Strand Separation and Sequencing 
To 438µl of annealing buffer, 2µl of 100µM sequencing primer was added to 
give a final concentration of 0.4µM. 40µl of annealing solution was added to 
wells of a pyrosequencing (PSQ) low plate which corresponded to the plate map 
in the PyroMark
 
ID software.  
The Vacuum Prep Workstation was prepared to the manufacturer’s protocol 
briefly; position 1 was filled with 110ml of 70% ethanol, position 2 with 90ml of 
denaturation solution, position 3 with 110ml wash buffer, and position 4 and the 
parking position were filled with RNAse free molecular grade water.   
The filter probes were washed with RNAse free molecular grade water from the 
parking position, with the use of the vacuum. 
The PCR plate and a PSQ low plate were placed on the vacuum prep workstation 
and the beads from the PCR plate were captured by vacuum onto the filter probes. 
The filter probes were then washed in ethanol at position 1 for 5 seconds, 
denaturation solution at position 2 for 5 seconds, and then in washing buffer at 
position 3 for 10 seconds. All the fluid from the filter probes was then allowed to 
flush away before the vacuum was turned off. 
The filter probes were then placed into the PSQ low plate containing the 
annealing solution and sequencing primer and agitated to release the beads. The 
PSQ low plate was then transferred into the PSQ 96 sample prep thermoplate low 
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on a heating block and incubated at 80
o
C for 2 minutes. The plate was then 
removed and allowed to cool. 
The PSQ low plate and the reagent cartridge were placed into the pyrosequencer, 
and the cover closed. The assay was then carried out.  
The stages of pyrosequencing were described previously (section 1.10.1). 
2.7.6. Result Interpretation: 
The PyroMark
 
ID software was used to generate a pyrogram for each sample 
tested. The pyrogram is a reading of relative light intensity released as each 
nucleotide base is incorporated to the sequence.  
The software uses a default set of criteria (including width of peaks, signal to 
noise ratio and possible dispensation errors) to read the sequence generated for 
each sample and the viability of each sequence produced. According to the match 
of the results to the criteria, the software assigns a colour to the results. Blue for 
passed, Amber for check results, ie a person is needed to verify the results and 
Red for failed.  
The software is able to calculate allele quantification or the percentage of 
sequence type present. For example a clinical sample of influenza can contain 
viruses with H (CAT) at position 274 and also viruses with Y (TAT) at position 
274. This dual or multi population is known as a quasi-species, meaning that you 
have a number of viruses with differing genetic make-up. Therefore for the H1N1 
assays a reading of C 5% and T 95%, shows that 5% of the population possesses, 
H (CAT) at position 274 and the remaining 95% of the population possesses Y 
(TAT) at position 274. 
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3. Results: 
3.1. Assay Optimisation: 
In order to establish robust methods for determining the presence of 
neuraminidase mutations it was essential to optimise methods from cDNA 
generation to pyrosequencing, in relation to the scientific literature and the 
protocols established by the commercial companies. 
H1N1 and H3N2 control material was used to optimise all the assays relevant to 
their subtype. Three aliquots of each subtype with varying CT values were put 
through each of the amplification assays stated below, and then through their 
subtype pyrosequencing assays. Any invalid results were repeated at least once to 
check results were due to amplification and not technical issues. 
The H274Y was the first assay to be optimised due to this mutation being the 
most relevant.  
The H274Y assay for H1N1pdm09 viruses was optimised using samples only due 
to the absence of stock control virus and the abundance of samples. 
3.1.1. Superscript III RT/Platinum Amplification Reagents: 
The study initially utilised the Superscript III RT/Platinum amplification reagents 
to generate cDNA, and the amplification of the target sequence down stream of 
pyrosequencing. This was found to produce unsatisfactory results. Samples 
treated in this way did not produce amplified products of good quality for either 
the N1 or N2 mutation targets. Figure 13 represents a pyrogram resulting from the 
use of amplified product produced using the Superscript III RT/Platinum 
amplification reagents. The results obtained indicate that the sample tested did not 
contain enough amplified product, and that an alternate method of amplification 
should be considered. 
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Figure 13 – Control sample 2 H1N1. A pyrogram representing the results obtained 
from using amplified product produced by the Superscript III RT/Platinum 
amplification reagents. This shows that a sequence has failed to be identified. 
3.1.2. Superscript III HiFi Amplification Reagents: 
In order to significantly improve the quality of the amplified product for 
downstream pyrosequencing, the use of Superscript III HiFi amplification 
reagents were assessed. 
3.1.2.1. H274Y Assay for the Seasonal (pre 2009) N1 Viruses: 
The H274Y assay for the seasonal (pre 2009) N1 viruses performed using the 
superscript III HiFi amplification reagents gave good quality reproducible results 
using the reference strains (Figure 14), indicating that this method was more 
effective in generating cDNA and high quality amplified products from clinical 
material than the previous method employed. 
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Figure 14 – Sample 25. A pyrogram showing successful amplification and 
pyrosequencing. Sequence readout: TTC/TATTATG, mutation present in 96% of 
the quasi-species. 
 
3.1.2.2. D151 Assay for N1 Viruses: 
The D151 protocol using the Superscript III HiFi amplification reagents could not 
be optimised for routine use. The SNP analysis produced erroneous pyrograms, 
with wide peaks (Figure 15). Further optimisation work could not be undertaken 
in the time-frame of the study. 
This error usually results from the presence of too much nucleic acid for the used 
enzyme/substrate activity or a slow degradation of the pyrophosphate from the 
previous nucleotide incorporation, caused by decreased performance/activity of 
the enzyme (Qiagen 2013).  
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Figure 15 – Control sample 2 H1N1. Pyrogram results from the H1N1 D151 assay. 
This shows wide peaks which were unable to be interpreted by the pyrosequencing 
software. 
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3.1.2.3. Assays for the N2 Virus Mutations: 
The use of the Superscript III HiFi amplification reagents for the H3N2 mutations 
was unsuccessful using the sample input volume of 5µl as the H1N1 viruses (see 
figure 16) .  
 
 
Figure 16 – Control sample 5 H3N2. Pyrogram results from the amplification of the 
E119V target using 5µl of eluate. This shows that not enough amplified product was 
present to produce interpretable results. 
 
To optimise the assays for the H3N2 mutations using the Superscript III HiFi 
amplification reagents, the input volume of eluate for amplification was increased 
to 15µl (see figure 17). 
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Figure 17 - Control sample 5 H3N2. Pyrogram results from the amplification of the 
E119V target using 15µl of eluate. Sequence readout: AGGTTCTC, no mutation 
present. 
 
SNP analysis for the D151 and R292/4 point mutations for the N2 viruses could 
not be optimised and due to time constraints only SQA analysis was optimised for 
the clinical samples (Figure 18). 
 
Figure 18 – Control sample 5 H3N2. An example of a SQA pyrogram from the 
H3N2 D151 assay. Sequence readout: AGTACGTGATAGGACCCCTTA 
TCGGACCCTATTGATGAATGAG. No mutation present. 
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3.1.3. Qiagen One-Step RT-PCR Amplification: 
The Qiagen One-step RT-PCR amplification reagents were introduced during the 
course of this study to produce amplified product suitable for use with a 
pyrosequencer. These reagents were validated for use with the E119V assay 
developed by this study.  
Eight samples were used to compare the HiFi reagents with the Qiagen One-step 
RT-PCR amplification reagents. The Qiagen One-step RT-PCR amplification 
reagents produced better results than the Superscript III HiFi amplification 
reagents (see figures 19-22). Three of the samples tested produced results from 
the product amplified using the One-step RT-PCR amplification reagents that did 
not produce results with the Superscript III HiFi products.  
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Figure 19 - Sample 28 (CT 29). pyrogram produced using Superscript III HiFi 
amplification reagents. The sequence was able to interpreted, but needed to be 
checked, AGGTT/ACTG. 
 
 
 
Figure 20 - Sample 28 (CT 29). Pyrogram produced using Qiagen One-stpe RT-
PCR amplification reagents. Higher light intensity and better sequence viability, 
AGGTT/ACTC, 5% mutation present in quasi-species. 
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Figure 21 - Sample 7 (CT 40). Pyrogram results using Superscript III HiFi 
amplification reagents. Sequence unable to be interpreted. 
 
 
Figure 22 - Sample 7 (CT 40). Pyrogram results using Qiagen One-step RT-PCR 
amplification reagents. Sequence interpretable but needed to be checked, 
AGGTT/ACTC, 5% mutation present in quasi-species. 
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3.1.3.1. H274Y Mutation in H1N1pdm09 Viruses: 
Similar good quality results for the H274Y mutation in the H1N1pdm09 virus 
were obtained using the Qiagen One-step RT-PCR amplification reagents with an 
increase in sensitivity. The only change to the manufacturer’s protocols was the 
amount of template added (10µl instead of 5µl) to the amplification reagents.  
 
Figure 23 - Sample 103. Pyrogram result, sequence readout: ATC/TACTA, 2% 
mutation present in quasi-species. 
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3.2. Clinical Validation:  
3.2.1 Antiviral Susceptibility Testing of Pre-Pandemic Seasonal Influenza A 
H1N1: 
During the 2008-2009 season, 15 H1N1 samples were collected from the Welsh 
population and were tested for the H274Y mutation that confers high level 
resistance to oseltamivir. 
3.2.1.1. H274Y Mutation: 
Table 6 - Results of the clinical validation of the H274Y assay on H1N1 viruses pre-
2009. 
Sample 
ID 
H274 C% 
(wildtype) 
Y274 T% 
(mutation) 
3 F F 
4 1 99 
25 4 96 
27 2 98 
34 1 99 
35 3 97 
38 1 99 
47 1 99 
52 1 99 
53 6 94 
54 2 98 
67 1 99 
70 1 99 
74 1 99 
76 F F 
  F= failed to produce interpretable pyrograms. 
Following amplification and SNP analysis by pyrosequencing, 3 of the 15 
samples produced invalid results. The remaining 12 samples were successfully 
amplified giving good results and possessed H274Y quasi-species of 94-99%. 8 
of these samples were also tested using the HPA, Colindale primers. This assay 
showed all 8 samples to possess the H274Y mutation at a level of 100%. 
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Table 7 - Results of Colindale primers for the H274Y mutation in H1N1 pre-2009 
viruses. 
Sample 
ID 
H274 C% 
(wildtype) 
Y274 T% 
(Mutation) 
47 0 100 
52 0 100 
53 0 100 
54 0 100 
67 0 100 
70 0 100 
74 0 100 
76 0 100 
 
 
Figure 24 - Sample 4. Sequence readout: TTC/TATATG, 99% mutation present in 
the quasi-species. 
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3.2.2. Antiviral Susceptibility Testing of Influenza A H3N2 Viruses: 
A total of 53 H3N2 positive samples were amplified and tested for the mutations 
associated with reduced sensitivity to the NAIs including E119V, and the 
mutations found at positions D151 and R292/N294. 
3.2.2.1. E119V Mutation: 
Table 8 - Results of the clinical validation of the E119V assay on H3N2 viruses. 
Sample 
ID 
CT 
value 
E119 T% 
(wildtype) 
 V119 A% 
(mutation) 
2 39 F F 
5   F F 
6 38 100 0 
7 40 F F 
8 40 F F 
9 39 F F 
10 32 96 4 
11 36 100 0 
14 30 100 0 
26   87.5 12.5 
28 29 97 3 
29 27 100 0 
30 38 F F 
31 26 87 13 
32   100 0 
33 37 100 0 
36 36 F F 
37 32 92 8 
39 35 F F 
40 38 F F 
41 28 100 0 
42 30 97 3 
44 31 79 21 
45 32 100 0 
46 30 90 10 
48 27 97 3 
49 36 88 12 
50 34 69 31 
51 25 96 4 
55 37 100 0 
56 39 F F 
57 32 100 0 
58 33 86 14 
59 36 F F 
60 35 F F 
61 27 96 4 
62 39 F F 
63 37 100 0 
64 41 F F 
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65 36 F F 
66 30 100 0 
68 31 72 28 
69 26 97 3 
71 25 97 3 
72 34 100 0 
73 30 100 0 
75 37 100 0 
77 31 82 18 
78 26 95 5 
79   93 7 
    F = Failed to produce interpretable pyrograms, Sample = >10% mutation 
Following amplification and SNP analysis for the E119V point mutation by 
pyrosequencing, 17 of the samples produced invalid results.  
  
Figure 25 - Sample 56. Failed to produce interpretable results. 
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Of the remaining samples, 15 had no detectable E119V mutation present.  
 
Figure 26 - Sample 41. Sequence readout: AGGTT/ACTC, no mutation present. 
 
Using the allele quantification function on the pyrosequencer it was shown that 
12 samples had a low level (1-7%) of detectable E119V mutation within the viral 
quasi-species.
 
Figure 27 - Sample 78. Sequence readout: AGGTT/ACTC, 5% mutation present in 
the quasi-species. 
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Nine samples had an elevated population (8-31%) of E119V resistant virus in the 
quasi-species. 
 
Figure 28 - Sample 31. Sequence readout: AGGTT/ACTC, 13% mutation present in 
the quasi-species. 
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3.2.2.2. D151 Mutation: 
SQA analysis for the D151 mutations was performed on 26 of the 53 samples. 
Only 9 samples produced results and sequences that matched H3N2 N sequences. 
These 9 samples showed no mutations at position 151. The remaining samples 
produced invalid results.  
 
Figure 29 - Sample 51. Sequence readout: AGTACGTGATAGGACCCCTTATCG 
GACCCTATTGATGAATGAG, No mutation present. 
 
Figure 30 - Sample 30. Invalid SQA D151 assay. Sequence readout does not match 
H3N2 reference strains, GATGGATGACGGTGGATGAGGACCCTTGAT 
GCGGACCTGATGGATGGAATGGAGG 
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3.2.2.3. R292/N294 Mutation: 
SQA analysis for the R292/N294 mutations was performed on 44 of the 53 
samples. Only 16 samples produced results and sequences that matched H3N2 N 
sequences. These 16 samples showed no mutations at positions 292 or 294. The 
remaining samples gave invalid result. 
 
Figure 31 - Sample 14. Sequence readout: TTTCCAGTTGTCTCTGCAGACAC 
ATCTGACACCA, no mutations present. 
 
Figure 32 - Sample 30. Invalid SQA R292/N294 assay. Sequence readout does not 
match H3N2 reference strains: TGACTGACTGACTGGACTGACTGAC 
TGACTGACTGACTGACTGACTGACTGACTGACTGA. 
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3.3. Clinical Validation of Influenza A H1N1pdm09 Viruses: 
3.3.1. Antiviral Susceptibility Testing of H1N1pdm09 Viruses:  
A cohort of 121 H1N1pdm09 samples were tested using the Qiagen One-Step 
RT-PCR (Limburg, The Netherlands) amplification reagents and SNP analysis on 
the pyrosequencer for the H274Y point mutation with primers described by the 
WHO (2009a).  
Table 9 - Results of the clinical validation of the H274Y assay on H1N1pdm09 
viruses. 
Sample 
ID 
CT 
 
H274 C% 
(wildtype) 
Y274 T% 
(mutation) 
12   88 12 
13   97 3 
15   98 2 
16   96 4 
17   96 4 
18   98 2 
19   98 2 
20   98 2 
21   97 3 
22   97 3 
23   97 3 
24   95 5 
81   SQA   
82   SQA   
83   96 4 
84   97 3 
85   SQA   
86   SQA   
87   SQA   
88   SQA   
89   SQA   
90   SQA   
A 42 F F 
B   100 0 
C 30 100 0 
D   100 0 
E NEG F F 
F   100 0 
G   97 3 
H   100 0 
92   95 5 
93   F F 
94   98 2 
95   95 5 
96   95 5 
97   95 5 
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98   98 2 
99   F F 
100   97 3 
101   97 3 
102   98 2 
103   97 3 
104   97 3 
105   91 9 
106   98 2 
107   96 4 
108   95 5 
109   95 5 
110   93 7 
111   98 2 
112   100 0 
113   97 3 
114   95 5 
115   F F 
116   F F 
117   97 3 
118   F F 
119   F F 
130   8 92 
131   0 100 
132   F F 
133   F F 
134   F F 
135   F F 
136   F F 
137   F F 
138   100 0 
139   58 42 
140   100 0 
141   51 49 
142   99 1 
143   100 0 
144   99 1 
145 26 100 0 
146 31 100 0 
147 33 F F 
148 36 F F 
149 33 F F 
150 25 97 3 
151 35 93 7 
152 26 98 2 
153 27 99 1 
154 26 99 1 
155 32 F F 
156 28 100 0 
157 36 F F 
158 28 99 1 
159 29 98 2 
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160 37 F F 
161 29 96 4 
162 20 98 2 
163 28 100 0 
164 29 100 0 
165 28 100 0 
166 23 97 3 
167 18 99 1 
168 21 99 1 
169 23 93 7 
170 35 98 2 
171 33 91 9 
172 35 96 4 
173   0 100 
174   97 3 
175   96 4 
176   100 0 
177   98 2 
178   F F 
179   90 10 
180   93 7 
181   89 11 
182   92 8 
183   99 1 
184   100 0 
185   99 1 
186   100 0 
187   100 0 
188   100 0 
189   F F 
190   98 2 
  F = Failed to produce interpretable pyrograms,     
  Sample = polymorphism samples, Sample = >10% mutation   
  SQA results only. 
Of the 121 samples analysed, 23 samples produced invalid results. The majority 
of the remaining samples possessed a low detectable level (1-10%) of H274Y 
resistant virus in the quasi-species. 
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Figure 33 - Sample 144. Sequence readout: ATC/TACTA, showing 1% mutated 
virus in the quasi-species. 
 
Only 18 samples produced results without any mutation present and one sample 
was shown to possess 100% resistant virus population. 
 
Figure 34 - Sample 173. Sequence readout: ATTACTA. 100% mutation present. 
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8 samples were also run through the SQA assay to check the assay quality. These 
samples showed no change in the neuraminidase sequence. 
From the SNP analysis it was also observed that 3 samples (from the 2010-2011 
season) had a sequence of TACCAC from position 273 instead of TATCAC, 
indicating a polymorphism in the H1N1pdm09 virus species. 
 
Figure 35 - Sample 176. Pyrogram showing the difference in sequence readout, 
ACCACTA instead of ATCACTA for the samples containing the polymorphism at 
position 273. 
 
Consecutive samples were collected from 3 patients who were receiving 
oseltamivir therapy during the 2010-2011 season to look for the emergence of 
NAI resistance. The first samples from 2 of these patients showed the absence of 
resistant virus. In the consecutive samples from these 2 patients a detectable level 
of 42% and 49% resistant virus was observed. The samples from the 3
rd
 patient 
showed an increase in resistant virus in the quasi-species from 1% in sample 1 
(day 2 of illness), to 92% in sample 2 (day 10 of illness) to 100% in sample 3 
(day 13 of illness) (See section 3.3.1.).  
3.3.1. Case Study: 
A 2 year old girl presented at A+E with status epilepticus. She had a 1 day history 
of feeling unwell and high temperature. She had had seizures during the day 
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which were treated with buccal midazolam but then developed an ongoing seizure 
which resulted in her removal to hospital. On admission to A+E she was treated 
for her seizures with 2 doses of rectal diazepam, 2 doses of intraosseal lorazepam; 
however she continued to fit so she was started on a phenytoin infusion. She 
developed bradycardia with a heart rate of 40/min requiring CPR for 1 minute. 
She was given a dose of adrenaline and an adrenaline infusion. She was also 
given100ml/kg IV fluid bolus and started on IV ceftriaxone. 
She was intubated and transferred to PICU. The patient was sent for a chest x-ray 
which revealed bilateral airspace shadowing, which was more extensive on the 
right. This was indicative of oedema or infection. The patient was stared on bi-
daily doses of 45mg oseltamivir. 
An NPA was performed on day 1 and the sample sent for IF for respiratory 
viruses. This produced a positive result for Influenza A. 
The patient was sedated with morphine, midazolam and chloral hydrate whilst she 
was ventilated. 
A second chest x-ray was performed 3 days after admission after increased 
oxygen intake. It revealed progressive bilateral shadowing and a right-sided 
pleural effusion; therefore a chest drain was inserted. 
The patient had a focal seizure on day 4 which was treated with IV lorazepam. On 
day 5 her chest drain was removed and she was extubated on day 6 and given a 
60% oxygen facemask. Another chest x-ray was performed on day 7, which 
showed bilateral haziness. 
Whilst on PICU the patient was given IV cefotaxine for her pyrexia and 15ml/kg 
packed red cells and 20ml/kg FFP. She was also given Vitamin K for prolonged 
PT. 
After completing a 10 day course of oseltamivir and cefotaxine, and having 
reduced need for oxygen and an increase in feeding. The patient was transferred 
to a General Paediatric ward. Here she was given bi-daily dose of keppra 300mg, 
sodium valporate 360mg and lamotrigine 25mg. She was also kept on chloral 
hydrate 900mg every 4-6 hours. She was now on a self-ventilating 5L facial 
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oxygen mask and having chest physiotherapy. A nose swab was taken for 
respiratory virus testing and was positive for H1N1 pdm09 influenza virus. 
The samples taken for respiratory testing were tested for influenza A, B and RSV 
by a real-time PCR assay performed on the Applied Biosystems Fast 9500. This 
found the samples to be positive for Influenza A. These samples were then typed 
by a similar assay performed on the Fast 9500, showing them to be positive for 
H1N1 pdm09.  
After noting that the patient was still positive after 10 days of oseltamivir 
treatment the samples were tested for the point mutation H274Y which confers 
oseltamivir resistance by using the Qiagen Pyromark ID pyrosequencer.  
The sample taken on day 1 contained 1% of virus species with the H274Y 
mutation (Figure 36). The next sample taken on day 9 contained 92% of virus 
species with the mutation (Figure 37). And a third sample taken on day 14 
contained 100% virus species with the mutation (Figure 38). 
 
Figure 36 - Pyrogram from sample 1, taken on day 2 of illness, showing 1% mutated 
virus in the quasi-species. 
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Figure 37 - Pyrogram of sample 2, taken on day 9 of illness, showing and increase to 
92% mutated virus in the quasi-species.  
 
 
Figure 38 - Pyrogram of sample 3, taken on day 14 of illness, showing 100% 
mutated virus. 
This patient had a previous history of epilepsy which had resulted in two 
admissions to hospital in the last year, and it was also noted that she was mildly 
delayed in her physical development. Apart from these factors there are no further 
medical history of importance and no history of reduced immunity.   
Although the patient was extremely ill at the start of her illness, she had vastly 
improved when her second respiratory sample was taken (which showed 92% 
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resistance) and had been off oseltamivir for 3 days when her third sample was 
taken (100% resistant).  
An underlying level of less than 10% mutated has been shown in the majority of 
H1N1 pdm09 samples tested in this study, but the relevance of this low level is at 
the moment uncertain. This case study has shown that there may be a need to 
monitor the patients who present with a low level of resistant virus at the start of 
their illness especially if they are given oseltamivir. The longevity of symptoms 
may have been reduced if her resistance level was regularly monitored from the 
onset of her illness and if she was able to be given zanamivir, as soon a rise in 
mutated virus was noted, if not at the very beginning of her illness. 
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4. Discussion: 
4.1. Assay Optimisation: 
4.1.1. H274Y Assay for Seasonal H1N1 Viruses (Pre 2009): 
The H1N1 assay for the H274Y point mutation was optimised for routine 
diagnostic use, with one change to the protocol described by Deyde et al (2009b). 
The use of the Superscript III HiFi amplification reagent kit (Invitrogen
™
, Life 
Technologies
™
, California, USA), instead of the Superscript III RT/Platinum 
amplification reagents (Invitrogen
™
, Life Technologies
™
, California, USA). This 
reagent kit allowed the production of good quality amplified products which 
produced good results. This protocol was easy to perform and had a hands-on 
time, from amplification to results, of about 30 minutes and a total time of about 
4 hours. This assay could therefore be performed on the same day as a positive 
influenza A H1N1 result was identified, especially as the same sample extract 
could be used. 
The primers routinely used by HPA Colindale in a similar pyrosequencing assay, 
were validated in comparison with the Deyde et al (2009b) assay for 8 samples. 
The samples tested using the HPA Colindale primers gave results showing 100% 
levels of mutated virus. In comparison the same samples produced variable levels 
of 94-99% of mutated virus by the optimised Deyde et al (2009b) assay. This 
variation is minimal but could be due to differences in the target regions of the 
assays and how well each assay amplifies the entire quasi-species rather than 
simply the predominant species. 
4.1.2. D151 Assay for Seasonal H1N1 Viruses (Pre 2009): 
The D151 protocol described by Deyde et al (2009b) could not be optimised for 
routine use. The SNP analysis produced erroneous pyrograms, with wide peaks. 
This error usually results from the presence of too much nucleic acid for the used 
enzyme/substrate activity or a slow degradation of the pyrophosphate from the 
previous nucleotide incorporation, caused by decreased performance/activity of 
the enzyme (Qiagen, 2013). This error may be rectified by decreasing the amount 
of nucleic acid used as a template in the initial amplification step. Due to time 
 68 
 
constraints this error was not able to be investigated further. From the point of 
view of the smooth running of laboratory assays, it is important to standardise 
sample preparation for downstream assays, but this is an area for potential future 
optimisation.  
4.1.3. E119V Assay for H3N2 Viruses: 
The E119V protocol described by Deyde et al (2009b) was easily optimised for 
routine use using the Superscript III HiFi amplification reagent kit (Invitrogen
™
, 
Life Technologies
™
, California, USA) and by adding a degeneracy to the reverse 
primer and the amount of target added for amplification. After optimisation this 
assay was easy to perform and had a hands-on time, from amplification to results, 
of about 30 minutes and a total time of about 4 hours. This assay could therefore 
be performed on the same day as a positive influenza A H3N2 result was 
identified, especially if the same sample extract could be used. 
Consistent and reproducible results were also obtained using the Qiagen One-Step 
RT-PCR amplification kit (Limburg, The Netherlands). There was a notable 
increase in sensitivity as the assay was further optimised to double the amount of 
amplification primer and also the amount of starting template in the initial PCR. 
The significant reduction in the overall cost of the reagents when compared to the 
HiFi reagents means that the assay is more cost effective per sample sequenced. 
4.1.4. R292K and N294S Assay for H3N2 Viruses: 
The Deyde et al (2009b) assay for SNP analysis for the R292K and N294S 
mutations could not be optimised for routine use due to difficulties in SNP calling 
across the two positions. Therefore SQA analysis was performed for these 
mutations. This assay takes longer than the SNP analysis assays optimised for the 
H274Y and E119V mutations. However it does produce a gene sequence of up to 
100bp. This analysis allowed known mutations to be identified and also has the 
potential to allow identification of new mutations in the target region.  
4.1.5. D151 Assay for H3N2 Viruses: 
SQA analysis was performed for the D151 mutations. This assay is most optimal 
for this mutation as it has been well documented that many different mutations 
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can occur at codon 151. However it has been documented that these mutations are 
usually cell culture derived and therefore unlikely to be seen when testing directly 
from the sample (Okomo-Adhiambo et al, 2010). The lack of the mutation in 
clinical samples was therefore not unexpected and in light of the requirement to 
culture the virus first, it is unlikely that this assay would be suitable for routine 
application.   
4.1.6. Assessment of One-Step RT-PCR Amplification Kit: 
The E119V assay was utilised to assess the Qiagen One-Step RT-PCR 
amplification kit (Limburg, The Netherlands). This amplification kit allowed the 
amplification of samples that were unable to be amplified using the Superscript 
III HiFi amplification reagent kit (Invitrogen
™
, Life Technologies
™
, California, 
USA). This is possibly due to the increased concentration (0.8µM compared to 
0.4µM) of the amplification primers. 
4.1.7. H274Y Assay for H1N1pdm09 Viruses: 
The Qiagen One-Step RT-PCR amplification kit (Limburg, The Netherlands) was 
used for the amplification of the H1N1pdm09 isolates. This kit produced good 
quality amplified product in conjunction with the primers described by the WHO 
(2009a) and produced good results. This protocol was easy to perform and had a 
hands-on time, from amplification to results, of about 30 minutes and a total time 
of about 4 hours. This assay could therefore be performed on the same day as a 
positive influenza A H1N1pdm09 result was identified, especially if the same 
sample extract could be used. 
This assay is now in routine use at PHW Microbiology Cardiff. 
Assay optimisation for this study was achieved by making changes to the 
amplification kit reagents used and adjustment of the stated manufacturer’s 
protocols and input volumes for amplification.  
Further changes in optimisation could have been performed at many other steps in 
the process if time and money allowed. The main changes worth exploring would 
have been primer concentration. A more regimented approach of a standard 
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increase or decrease of 0.5µM intervals of concentration may have produced 
better comparisons for results.  
Steps in the pyrosequencing protocol could also be regimented and small changes 
made to determine effect on the pyrosequencing results, such as length of 
incubation times and speed of mixing.   
Invalid results were often observed due to technical issues with the vacuum 
station. A more advanced vacuum station with a reduction in pressure issues 
would be very valuable for this type of assay. 
4.2. Clinical Validation: 
All of the samples to be used for clinical validation were tested by the new In-
house assay to determine the strength of the positive result of the samples. The 
In-house assay is not quantifiable but the CT value does give an indication of how 
much virus is present. It was found that the samples with a high CT value (greater 
than 39) were unable to produce enough amplified product to produce valid 
results, whereas samples with a CT value of 34 or lower were able to be amplified 
sufficiently. Samples with a CT value between 34 and 39 were sporadic in the 
production of sufficient amplified product to produce interpretable results. 
Therefore the majority of invalid results noted during clinical validation are due 
to the amount of virus present in the original clinical sample. 
4.2.1. Antiviral Susceptibility in Seasonal H1N1 Viruses (pre 2009): 
4.2.1.1. H274Y Mutation: 
During the 2007-2008 respiratory season, an increase in the presence of 
oseltamivir resistant viruses of up to 70% was observed (Lackenby et al, 2008a). 
By the next respiratory season (2008-2009) the levels were nearly 96% in Britain 
(NISN, 2010). The results from this study reflect these findings and suggest that 
the levels of oseltamivir resistant H1N1 viruses in Wales (pre 2009), was close to 
100%. Such information is important to clinicians in their assessment of patients 
and determination of appropriate treatments. 
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4.2.2. Antiviral Susceptibility of H3N2 Viruses: 
4.2.2.1. E119V Mutation: 
The E119V mutation was detected in 21 of the 53 samples tested. The amounts 
present in the virus quasi-species varied from 1-31%. These levels could suggest 
a possibility of resistance occurring in these individuals if they were treated with 
oseltamivir and/or were immunocompromised. The E119V mutation was 
identified early in the use of NAI’s, and has only been documented outside the 
cell culture setting as the cause of oseltamivir resistance in several cases of 
treated individuals (Kiso et al, 2004; Sheu et al, 2008). Therefore it is possible 
that the samples with the presence of resistant virus could be from individuals 
already treated with oseltamivir. However this is unlikely, as most of the samples 
tested were initial diagnosis samples and therefore treatment would not have 
commenced at the time the sample was taken. Surveillance for this particular 
mutation is warranted as the results from this study suggest a possible increase in 
incidence. 
4.2.2.2. R292K/N294S Mutations: 
The mutation at R292K was one of the first mutations identified for H3N2 viruses 
in relation to the NAI’s during challenge studies (Gubareva et al, 1996; Gubareva 
et al, 1997; McKimm-Breschkin et al, 1998). This mutation was associated with 
oseltamivir resistance in children infected with H3N2 viruses and treated with 
oseltamivir (Kiso et al, 2004). 
The N294S mutation was also identified in children infected with H3N2 viruses 
and treated with oseltamivir (Kiso et al, 2004). However, this mutation has now 
been noted more frequently in H5N1 isolates (Le et al, 2005; Earhart et al, 2009). 
Only 16 samples from this study produced valid sequences and none of these 
samples possessed R292K or N294S mutations at these positions. It is therefore 
suggested that these mutations only arise in H3N2 infected individuals when 
treated with NAIs.  
These mutations have also been observed more recently, in oseltamivir treated 
immunocompromised patients after 8 (R292K in one patient) and 7 (N294S in a 
2
nd
 patient) days of treatment respectively (Piralla et al, 2013). 
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These cases are likely to have occurred due to the increased viral shedding 
observed in children and the immunocompromised. 
4.2.2.3. D151 Mutation: 
Only 9 samples produced results that matched the neuraminidase sequences of 
H3N2 viruses. The sequences produced from the SQA analysis for the D151 
mutation showed no evidence of mutations at this position.  
Again mutations at this position have mainly been observed in viruses grown in 
cell culture and have not been identified directly from clinical samples (Okomo-
Adhiambo et al, 2010). 
4.2.2.4. Invalid SQA results: 
The SQA assays for the R292K/N294S and D151 assays for the H3N2 viruses 
were the last of the assays to be optimised. Use of sample in the E119V assays 
and the repeat assays performed due to the production of invalid results due to 
technical issues, caused a small amount of sample to be available for testing. 
Many of the SQA assays returned invalid results that could not be investigated 
further due to lack of sample, but due to the return of sequences that did not 
match the target sequence it is possible that the sample may have been degraded 
resulting in these unknown sequences. 
4.2.3. Antiviral Susceptibility of H1N1pdm09 Viruses: 
4.2.3.1. H274Y Mutation: 
In total, 98 samples produced valid results. Of these, 18 samples had no evidence 
of the H274Y mutation present in the virus, and 7 samples had evidence of 
resistant virus within the viral quasi-species of between 10% and 100%. Of these 
7 samples, 4 were repeat specimens taken from patients who had had previous 
samples with no or low level resistant virus. In the UK, 72 cases of oseltamivir 
resistance in H1N1pdm09 viruses were recorded between May 2009 and 
February 2011. These cases were mainly in the immunocompromised or those 
who were exposed to oseltamivir (Lackenby et al, 2011).  
One of these 7 samples showed 100% mutated virus. It is unknown whether this 
patient had contact with a H1N1pdm09 positive individual, who had had or was 
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taking oseltamivir, and whether they were known to be infected with resistant 
virus. During the 2010-2011 season, 3 cases of oseltamivir resistance were 
reported from community patients in the UK (Lackenby et al, 2011), and a case of 
H1N1pdm09 virus containing a mixed population of mutant (Y274-52.6%) and 
wild-type (H274-47.4%) virus from an immunocompetent, treatment naïve 
individual was reported in Hong Kong in 2009 (Chen et al, 2009). 
The remaining 73 samples had a low level (1-10%) of resistant virus present. The 
significance of the presence of low levels of resistant virus is currently unclear. 
As seen in this study and worldwide, low level or even no resistant virus present 
at first sampling can increase up to 100% resistant virus in the presence of 
oseltamivir, which is most often observed in the immunocompromised (Inoue et 
al, 2010; Memoli et al, 2010; Nguyen et al, 2010a; Yi et al, 2010; Moore et al, 
2011).  
4.2.3.2. Polymorphism: 
It was observed that 3 samples from the 2010-2011 season showed the presence 
of a base change in codon 273, TAT instead of TAC. This codon change is silent 
in that it does not produce a change in amino acid, and is unknown if it would 
have any positive or negative effect on the virus. 
4.2.3.3. Patient Management: 
This study did not have any impact on patient management during the period of 
testing, as the majority of testing was performed retrospectively, and the assays 
had not been validated to be used routinely.   
The presence of low levels of resistant virus in patient samples has led to a 
discussion on whether or not it is suitable to keep these patients on oseltamivir. 
The agreed WHO strategy states that if the presence of resistant virus is >50% it 
is clinically and epidemiology relevant. It also suggests that quasi-species with 
<50% resistant virus present should be reported to the clinicians as resistant for 
patient management, but not for international records (Lackenby et al, 2011).  
The PHE (formally HPA) in the UK released new guidance notes for healthcare 
practitioners on the use of antiviral agents for the treatment and prophylaxis of 
influenza from the start of 2014 (Figure 39) (Parry-Ford, 2013). 
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Figure 39 - Algorithm for the selection of antiviral therapy for the treatment of 
influenza (Parry-Ford, 2013). 
 
NAI’s are only suggested for use if the clinician feels the patient is at risk from 
complications.  
Due to the observation of oseltamivir resistance developing in 
immunocompromised individuals these guidelines recommend the use of 
zanamivir instead of oseltamivir in this patient group. The emergence of 
oseltamivir resistant viruses should be tested for if the patient’s condition has not 
improved after five days of treatment. These guidelines also warrant the use of 
zanamivir in its unlicensed forms via nebulisation and IV if the patient is unable 
to take or benefit from the disk-inhaler. It is also recommended that zanamivir be 
given for up to 10 days if resistance to oseltamivir is confirmed or suspected and 
also in patients who have been in contact with a confirmed or suspected case of 
oseltamivir resistant influenza (Parry-Ford, 2013). 
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4.2.4. Further Clinical Validation: 
4.2.4.1. Untypeable Influenza A Samples: 
The original subtyping assay performed by the Molecular Diagnostics unit during 
the 2008-2009 season was unable to type 3 of the influenza A isolates. These 
samples were put through all of the mutation assays to see if their subtype was 
identifiable. Only 1 sample was detected in any of the assays, the E119V SNP 
assay, which showed the sample to be 100% susceptible to NAI’s and determined 
that this sample contained an N2 influenza virus.  
4.3. Other Mutations: 
Several new mutations have been noted on their own, or in conjunction with other 
already known mutations, to cause reduced susceptibility to NAI’s. The most 
noted of these is I222 (223 in N1 numbering). 
Isoleucine (I) 222 is a framework residue which helps to stabilize the formation 
of the binding site for sialic acid (Colman et al, 1983). Reverse genetics has 
shown that a mutation at this position can cause reduced susceptibility to NAIs. 
Depending on the amino acid the mutation results in, can cause varying amounts 
of reduction of susceptibility to NAI’s (Richard et al, 2008). A change to leucine 
(L) can cause a reduction in sensitivity to zanamivir by up to 10 fold (compared 
to wild-type virus in inhibition assays) and to oseltamivir by 18 fold in N2 viruses 
(Richard et al, 2008). Baz et al (2006) noted a mutation of isoleucine to valine 
(V) at position 222 in conjunction with the E119V mutation. The virus was 
isolated from an immunocompromised child after 38 days of oseltamivir 
treatment and is believed to reduce the susceptibility of oseltamivir even further 
(IC50 value of 1011nmol/L) than if the virus possessed the E119V mutation alone 
(IC50 value of 452nmol/L) (Baz et al, 2006).  
I222V has also been reported in H1N1pdm09 viruses on its own and in 
conjunction with the H274Y mutation (Garrison et al, 2009). A change to 
arginine (R) has also been reported in conjunction with the H274Y mutation in 
H1N1pdm09 viruses in immunocompromised and competent individuals, leading 
to multidrug resistance (Nguyen et al, 2010a; van der Vries et al, 2010; Eshaghi et 
al, 2011). 
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A point mutation at position 136, CAG to AAG, resulting in an amino acid 
change from glutamine (Q) to lysine (K) has been observed in H1N1 viruses, 
causing resistance to zanamivir (Hurt et al, 2009). However this was not observed 
directly from clinical samples. The Q136K mutation has also been discovered in 
H3N2 viruses causing resistance to zanamivir, from patients with no history of 
NAI usage (Dapat et al, 2010). A GenBank search performed by Dapat et al 
(2010) as part of their study, showed that the Q136K mutation could be a 
naturally occurring mutation as NA sequences with this mutation were isolated in 
1995, before the worldwide use of NAI’s, and in 2003, 2004 and 2007  
A mutation at position 247 (N1 numbering) causing an amino acid change from 
serine (S) to asparagine (N) has been recorded in community patients in 
Australasia. This mutation causes a reduced susceptibility to oseltamivir and 
zanamivir, 6 and 3 fold difference versus wild-type virus, by NIA, respectively, 
and an increase in resistance to oseltamivir and peramivir when combined with 
the H274Y mutation (6000 fold difference versus wild-type virus compared to 
600 fold difference for the H274Y mutation alone) (Hurt et al, 2011). 
The amount of new and combination mutations being reported gives cause for 
concern especially as the only mutation tested for routinely is H274Y. It may be a 
better protocol to perform full influenza genome sequencing to highlight any 
mutations or deletions and also to perform inhibition assays to check the amount 
of susceptibility each mutation or combination of mutations results in.  
4.4. New Techniques: 
Since the start of this project in 2009 many genotypic protocols and techniques 
have been reported for the detection of the point mutations which can cause NAI 
resistance. These include real time RT-PCR assays (Bolotin et al, 2009; van der 
Vries et al, 2013), and other nucleotide based techniques (Steain et al, 2009; Liu 
et al, 2010; Duan et al, 2011; Miyoshi-Akiyama et al, 2012). However all these 
new genotypic techniques come to a similar conclusion in that they are limited by 
the knowledge of the mutations which cause resistance (Nguyen et al, 2012; 
Okomo-Adhiambo et al, 2012).  
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The WHO currently recommends; Sanger sequencing, Pyrosequencing or Real-
time RT-PCR allelic discrimination for the detection of NAI resistance in 
H1N1pdm09 viruses (WHO, 2014). However quicker, high through-put and more 
cost-effective molecular sequencing methods are now available, known as next 
generation or deep sequencing. These techniques are now widely used in viral 
research especially for identification of new viruses or new strains of known 
viruses especially in outbreak situations and in drug resistance (Quiñones-Mateu 
et al, 2014). These new techniques may be useful in the future detection of new 
mutations in the neuraminidase gene, but the relevance of the mutations 
discovered could not be verified without still performing some form of 
phenotypic assay to confirm that the mutation causes reduced susceptibility to the 
NAI’s. 
4.5. New Treatments: 
After the introduction worldwide of oseltamivir and zanamivir in 1999, further 
research has been conducted to develop other NAI’s and to research other aspects 
for influenza antivirals to target.  
4.5.1. Peramivir: 
Peramivir is an NAI based on the structure of sialic acid. It was developed in 
2000 as an alternative to oseltamivir and zanamivir (Babu et al, 2000).  
Peramivir is currently undergoing phase 3 clinical trials in America and was 
approved for use in Japan and South Korea in 2011. It has been shown to reduce 
the longevity of symptoms, has demonstrated a higher efficacy than zanamivir for 
H1N1 and H3N2 viruses and an efficacy similar to oseltamivir and has been well 
tolerated (Bantia et al, 2001; Gubareva et al, 2001b; Hernandez et al, 2011). The 
FDA in the USA, awarded the intravenous use of peramivir a FDA Emergency 
Use Authorisation (EUA) for use during the 2009 influenza pandemic (FDA, 
2009).   
Neuraminidase inhibition assays were performed in 2001 to compare the effect of 
various point mutations on the efficacy of peramivir compared to oseltamivir and 
zanamivir. The mutation at position at R292 showed variable levels of resistance 
to each NAI, whereas the mutation at H274 showed resistance to Peramivir, but 
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susceptibility to zanamivir and various mutations at position E119 showed 
varying levels of resistance with a change to aspartic acid (D) causing the greatest 
resistance (Gubareva et al, 2001b). The H274Y mutation in H1N1pdm09 strains 
has shown resistance to peramivir especially when the I222R mutation is also 
present (Memoli et al, 2010; Nguyen et al, 2010a). 
As peramivir is similar to the NAIs already licensed and has a varying effect on 
viruses containing the known mutations causing resistance to NAIs, it seems to 
only be useful if patients are not responding to other treatments and would benefit 
from intravenous administration. Zanamivir is now suggested to be used in an 
intravenous form (in the UK) if the patient is unable to tolerate inhalation (Parry-
Ford, 2013) and it would seem a better idea to use this on patients who are 
unresponsive to oseltamivir treatment, especially if infected with the H1N1pdm09 
strain, rather than peramivir.  
The concentration of zanamivir in epithelial lining fluid after doses of either i.v 
zanamivir (600mg twice a day) or inhaled zanamivir (10mg twice a day) has been 
studied. The first aliquot of BAL samples performed 12 hours post dose, showed 
a higher zanamivir concentration in the subjects given inhaled zanamivir, but 
subsequent aliquots showed higher concentrations in the subjects given i.v 
zanamivir. This difference is believed to be due to the first wash collecting fluid 
from the areas closest to the broncoscope and also the areas that will be most 
affected by an inhaled drug, whereas the later aliquots would be from deeper in 
the lungs, areas which inhaled drugs would be less likely to reach. Therefore i.v 
zanamivir is likely to affect the whole of the lungs and target all infected cells, 
rather than just the upper areas where inhaled zanamivir is likely to reach 
(Shelton et al, 2011). 
4.5.2. Laninamivir: 
Laninamivir was developed in 2010 and has been commercially available as 
Inavir
®
 in Japan since October 2010 (Yamishita et al, 2011). It is administered by 
inhalation like zanamivir but has shown greater efficacy with just one dose 
compared to the bi-daily dosing of oseltamivir and zanamivir. It has also been 
shown to be effective after one dose, up to 7 days pre-infection as prophylaxis in 
in vivo studies (Kubo et al, 2010). It has also shown great efficacy after single 
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doses of 40 and 20mg versus oseltamivir, against oseltamivir resistant H1N1 
viruses in children. However no noted differences in efficacy compared to 
oseltamivir, were observed when used to treat H3N2 or B viruses, except of 
course the dosing regimen (Sugaya & Ohashi, 2010). In adults the efficacy of 
laninamivir was similar to oseltamivir (Watanabe et al, 2010).  
4.5.3. Other Treatments: 
Many different areas are now being researched to discover new antivirals for the 
treatment of influenza. A review by Hayden (2012) compiled a list of these agents 
(Table 10). 
Some agents other than NAIs and their alternative routes of administration are in 
advanced clinical development. These include Favipiravir (T-705), DAS181 and 
Nitazoxanide. Favipiravir inhibits the RNA polymerase of influenza after it is 
metabolised by the infected cell (Furuta et al, 2009). It has shown equal efficacy 
to oseltamivir in phase 2 and 3 trials in Japan and other Asian countries, although 
an initial loading dose and dosage adjustments based on weight and maybe 
ethnicity maybe be required (Hayden, 2012). DAS181 is a combination of the 
catalytic site of the sialidase from Actinomyces viscosus and a cell surface 
anchoring domain of human amphiregulin (Malakhov et al, 2006). This sialidase 
removes the sialic acid receptors from both human and avian epithelial cells, thus 
preventing the binding of influenza. Nitazoxanide is a licensed anti-parasitic, 
which has shown inhibitory effects on the maturation of HA (Rossignol et al, 
2009). In phase 2 trials it has shown a reduction in symptoms by up to 20 hours 
and even a reduction in viral load (Hayden, 2012). These agents clearly need 
further studies before they can be licensed for use for the treatment of influenza 
but they seem worth investigating and especially as none of them have shown any 
sign of resistance under pressure tests (Hayden, 2012). 
Another treatment option is to combine treatments that are already available. A 
triple combination drug regimen (TCAD) of amantadine, ribavirin and 
oseltamivir has been shown to be highly synergistic in vitro, especially against 
amantadine and oseltamivir resistant isolates (Nguyen et al, 2010b). Some 
combinations have shown antagonistic effects, such as oseltamivir and zanamivir 
against H1N1pdm09 viruses in vitro, and in seasonal influenza in humans.  
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Table 10 - Investigational anti-influenza agents (adapted from Hayden, 2012) 
Drug Class Agent- IN-intranasal; IP-intraperitoneal; IV-intravenous; SC-subcutaneous 
NA inhibitors (NAIs) Peramivir (IV), zanamivir (IV), oseltamivir (IV) 
A-315675 (oral)( 
Long-acting NAIs 
(LANIs) 
Laninamivir (topical) 
ZNV dimers (topical) 
Conjugated sialidase DAS181 (topical) 
Protease inhibitors Aprotinin (topical, IV) 
HA inhibitors and 
viral binding agents 
Peptides- FluPep (topical), Entry Blocker (topical), HB80/36, 
Flufirvitide 
Arbidol (oral) 
Cyanovirin-N (topical) 
Iota-carrageenan (topical) 
Pentraxin PTX3 (IP) 
Polymer bound 6′ sialyl-N-acetyllactosamine (topical) 
CYSTUS052 (topical) 
Recombinant human galectin-1 (topical)( 
Polymerase 
inhibitors 
Ribavirin (oral, IV, inhaled 
Favipiravir/T-705 (oral 
Viramidine (oral) 
Antisense oligonucleotides (IV, topical) 
M gene Antisense oligonucleotide (AVI-7100) (topical, IV) 
NP inhibitors Nucleozin (IP) 
Antisense oligonucleotides (IV) 
Interferons IFN inducers- poly-ICLC (topical),  nitazoxanide (PO) 
RIG-I activator (5′PPP-RNA) (IV) 
Antibodies to viral 
proteins 
Convalescent plasma, hyperimmune globulin 
Anti-HA, M2e, NA, NP 
Other topical agents Cationic airway lining modulators (iCALM- topical) 
Surfactant nano-emulsions (topical) 
SOFA-HDV ribozymes targeting M, NS, NP 
Defective interfering particles (244 DI RNA in a cloned 
A/PR/8/34) 
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However this is likely to be due to the NAIs acting on the same target (Duval et 
al, 2010; Nguyen et al; 2010b). 
Other treatment options include, antibody therapy, inhibition of RNA, adjunctive 
therapies to reduce the pro-inflammatory response, and host cell targets instead of 
influenza itself (Hayden, 2012).  
Influenza treatment is still an ongoing discovery and maybe it will continue for 
another 50 years. Treatment needs to be found to help control disease progression 
and viral load especially in the immunocompromised, who are the worst effected, 
and most likely to develop drug resistance due to their long drug exposure. 
Treatment without the ability for resistance to occur would be the most beneficial. 
However maybe the fight for new treatment may come to an end with the 
development of a universal vaccine? 
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4.5.4. Universal Vaccine: 
The H, M (M1 and M2), NP and N proteins (mainly in influenza A viruses) are 
being investigated for use as the target antigens for universal vaccines (Table 11) 
(Subbarao & Matsuoka, 2013).  
Table 11 - Viral targets of universal vaccines (adapted from Subbarao & Matsuoka, 
2013). 
Protein Target Site Function of 
target 
Proposed mechanism of 
protection 
H Stem Fusion activity Inhibition of fusion, maturation of 
H, viral egress, and ADCC
* 
M2 M2e Ion channel Alveolar macrophages and Fc, 
ADCC*, Ab dependent NK-cell 
activity, Complement-mediated 
lysis 
NP T-cell and 
Ab epitopes 
T-cell stimulation 
and non-
neutralising Ab 
Cell lysis by CD8
+
 cytotoxic T 
lymphocytes (CTL), CD4
+
 T 
lymphocyte-mediated cytolysis 
and B cell stimulation 
M1 T-cell 
epitopes 
T-cell stimulation Cell lysis by CD8
+
 cytotoxic T 
lymphocytes (CTL), CD4
+
 T 
lymphocyte-mediated cytolysis 
and B cell stimulation 
N Conserved 
sialidase 
active site 
Sialidase Inhibition of viral spread 
*ADCC-Antibody-dependent cell cytotoxicity. 
The sequence for the extracellular domain of the M2 protein, M2e is conserved 
among human influenza viruses and is not subject to drift or shift and has not 
significantly altered its genetic code since the 1918 pandemic (Fiers et al, 2004). 
The frequency and level of naturally occurring Abs to this region in infected 
individuals is very low, so studies into the use of this region for vaccine use have 
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concentrated on ways to overcome the poor immunogenicity (Subbarao & 
Matsuoka, 2013). 
The NP and M1 proteins are conserved among influenza A viruses. These 
proteins are not extracellular and therefore only produce cellular immune 
responses (Subbarao & Matsuoka, 2013). Vector based and linear peptide-based 
antigen delivery, have shown to be promising with approximately 60% reduction 
in infection after a single intramuscular dose (Berthoud et al, 2011). Also a 
vaccine based on a recombinant protein containing multiple linear epitopes from 
H, NP and M1 proteins from both influenza A and B viruses has been well 
tolerated (Atsmon et al, 2012).  
Virus-like particles (VLPs) containing N1 N protein have been shown to produce 
Abs in mice and protect them from H1N1 and H3N2 viruses, and have also 
shown a reduction in virus replication. However it is believed that vaccines that 
are based solely on the N protein would not prevent infection (Subbarao & 
Matsuoka, 2013).  
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5. Conclusions: 
The aim of this study was to adapt and optimised a published protocol to detect 
the point mutations conferring NAI resistance in influenza A viruses, on a routine 
basis in a clinical setting. The assays for the detection of the H274Y mutation in 
H1N1 viruses and the detection of the E119V mutation in H3N2 viruses were 
able to be adapted for routine use. The other point mutations at positions D151 in 
H1N1 viruses and D151, R292 and N294 in H3N2 viruses were not able to be 
optimised to perform SNP analysis according to the protocol published by Deyde 
et al (2009b). SQA analysis was able to be performed for the H3N2 mutations. 
Clinical evaluation of these assays showed the presence of the H274Y mutation, 
91-100%, in all the H1N1 viruses isolated from the welsh population during the 
2008-2009 season. Nearly 50% of the H3N2 viruses detected during the 2008-
2009 season had the E119V mutation, 3-31%, and none of the isolates had 
mutations at positions D151, R292 or N294. The assay for the detection of the 
H274Y mutation in H1N1pdm09 viruses, published by the WHO in 2009, was 
also adapted and optimised for routine use. A clinical evaluation of 121 samples 
collected between April 2009 and February 2011, was performed. The H274Y 
mutation was observed in the majority of samples but mainly at levels less than 
10%.  
Since the start of this assay the main circulating strain of influenza A has been 
H1N1pdm09. Therefore the detection of the H274Y mutation in this species can 
be performed routinely in a clinical setting based on this study. Being able to 
perform this assay, as part of a routine screen, will be beneficial for patient 
treatment, as a resistance result could be available with 24 hours from sample 
collection. 
However, if a change in circulating strain occurs or a change in mutation 
conferring to NAI resistance then a new assay will need to be developed. 
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Appendices: 
Appendix I. Influenza Sequences: 
Sequences with mutation and primers marked: 
A/New Caledonia/20/99 (H1N1) 
1    atgaatccaa atcaaaaaat aataaccatt ggatcaatca gtatagcaat cggaataatt     
61   agtctaatgt tgcaaatagg aaatattatt tcaatatggg ctagtcactc aatccaaact 
121  ggaagtcaaa accacactgg agtatgcaac caaagaatca tcacatatga aaacagcacc 
181  tgggtgaatc acacatatgt taatattaac aacactaatg ttgttgctgg aaaggacaaa 
241  acttcagtga cattggccgg caattcatct ctttgttcta tcagtggatg ggctatatac 
301  acaaaagaca acagcataag aattggctcc aaaggagatg tttttgtcat aagagaacct 
361  ttcatatcat gttctcactt ggaatgcaga accttttttc tgacccaagg tgctctatta 
421  aatgacaaac attcaaatgg gaccgtaaag gacagaagtc cttatagggc cttaatgagc 
481  tgtcctctag gtgaagctcc gtccccatac aattcaaagt ttgaatcagt tgcatggtca 
541  gcaagcgcat gccatgatgg catgggctgg ttaacaatcg gaatttctgg tccagacaat 
601  ggagctgtgg ctgtactaaa atacaacggc ataataactg aaaccataaa aagttggaaa 
661  aagcgaatat taagaacaca agagtctgaa tgtgtctgtg tgaacgggtc atgtttcacc 
721  ataatgaccg atggcccgag taatggggcc gcctcgtaca aaatcttcaa gatcgaaaag 
781  gggaaggtta ctaaatcaat agagttgaat gcacccaatt ttcattatga ggaatgttcc 
841  tgttacccag acactggcac agtgatgtgt gtatgcaggg acaactggca tggttcaaat 
901  cgaccttggg tgtcttttaa tcaaaacttg gattatcaaa taggatacat ctgcagtggg 
961  gtgttcggtg acaatccgcg tcccaaagat ggagagggca gctgtaatcc agtgactgtt 
1021 gatggagcag acggagtaaa ggggttttca tacaaatatg gtaatggtgt ttggatagga 
1081 aggactaaaa gtaacagact tagaaagggg tttgagatga tttgggatcc taatggatgg 
1141 acagataccg acagtgattt ctcagtgaaa caggatgttg tggcaataac tgattggtca 
1201 gggtacagcg gaagtttcgt tcaacatcct gagttaacag gattggactg tataagacct 
1261 tgcttctggg ttgagttagt cagaggactg cctagagaaa atacaacaat ctggactagt 
1321 gggagcagca tttctttttg tggcgtaaat agtgatactg caaactggtc ttggccagac 
1381 ggtgctgagt tgccgttcac cattgacaag tag                                          
A/Hawaii/28/2007 (H1N1) 
1    atgaacccaa atcaaaagat aataaccatt ggatcaatca gtatagcaat cggaataatt 
61   agtctaatgt tgcaaatagg aaatattatt tcaatatggg ctagtcactc aatccaaact 
121  ggaagtcaaa acaacactgg aatatgcaac caaagaatca tcacatatga aaacagcacc 
181  tgggtgaatc acacatatgt taatattaac aacactaatg ttgttgctgg agaggacaaa 
241  acttcagtga cattggctgg caattcatct ctttgttcta tcagtggatg ggctatatac 
301  acaaaagaca acagcataag aattggctcc aaaggagatg tttttgtaat aagagaacct 
361  ttcatatcat gttctcactt ggaatgcaga accttttttc tgacccaagg cgctctatta 
421  aatgacaaac attcaaatgg gaccgtaaag gacagaagtc cttatagggc cttaatgagc 
481  tgtcctctag gtgaagctcc gtccccatac aattcaaagt tcgaatcagt tgcatggtca 
541  gcaagcgcat gccatgatgg catgggctgg ttaacaatcg gaatttctgg tccagacaat 
601  ggagctgtgg ctgtactaaa atacaacgga ataataactg gaaccataaa aagttggaaa 
661  aagcaaatat taagaacaca agagtctgaa tgtgtctgta tgaacgggtc atgtttcacc 
721  ataatgaccg atggcccgag taataaggcc gcctcgtaca aaattttcaa gatcgaaaag 
781  gggaaggtta ctaaatcaat agagttgaat gcacccaatt tttattatga ggaatgttcc 
841  tgttacccag acactggcat agtgatgtgt gtatgcaggg acaactggca tggttcaaat 
901  cgaccttggg tgtcttttaa tcaaaacttg gattatcaaa taggatacat ctgcagtgga 
961  gtgttcggtg acaatccgcg tcccgaagat ggagagggca gctgcaatcc agtgactgtt 
1021 gatggagcaa acggagtaaa agggttttca tacaaatatg ataatggtgt ttggatagga 
1081 aggaccaaaa gtaacagact tagaaagggg tttgagatga tttgggatcc taatggatgg 
1141 acaaataccg acagtgattt ctcagtgaaa caggatgttg tagcaataac tgattggtcg 
1201 gggtacagcg gaagtttcgt ccaacatcct gagttaacag gattggactg tataagacct 
1261 tgcttctggg ttgagttagt cagagggctg cctagagaaa atacaacaat ctggactagt 
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1321 gggagcagca tttctttttg tggcgttaat agtgatactg caaactggtc ttggccagac 
1381 ggtgctgagt tgccgttcac cattgacaag tagttcgttg aaaaaaa 
 
A/Moscow/10/99 (H3N2) 
1    atgaatccaa atcaaaagat aataacgatt ggctctgttt ctctcaccat tgccacaata 
61   tgcttcctta tgcaaattgc catcctggta actactgtaa cattgcattt caagcaatat 
121  gaatgcaact cccccccaaa caaccaagtg atgctgtgtg aaccaacaat aatagaaaga 
181  aacataacag agatagtgta tctgaccaac accaccatag agaaggaaat atgccccaaa 
241  ctagcagaat acagaaattg gtcaaagccg caatgtaaca ttacaggatt tgcacctttt 
301  tctaaggaca attcgattcg gctttccgct ggtggggaca tctgggtgac aagagaacct 
361  tatgtgtcat gcgatcctga caagtgttat caatttgccc ttggacaggg aacaacacta 
421  aacaacgggc attcaaatga cacagtacat gataggaccc cttatcggac cctattgatg 
481  aatgagttgg gtgttccatt tcatttggga accaagcaag tgtgcatagc atggtccagc 
541  tcaagttgtc acgatggaaa agcatggctg catgtttgtg taacggggga tgatgaaaat 
601  gcaactgcta gcttcattta caatgggagg cttgtagata gtattggttc atggtccaaa 
661  aaaatcctca ggacccagga gtcggaatgc gtttgtatca atggaacttg tacagtagta 
721  atgactgatg ggagtgcttc aggaaaagct gatactaaaa tactattcat tgaggagggg 
781  aaaatcgttc atactagccc attgtcagga agtgctcagc atgtcgagga atgctcctgt 
841  tatcctcgat atcctggtgt cagatgtgtc tgcagagaca actggaaagg ctccaatagg 
901  cccatcgtag atataaacat aaaggattat agcattgttt ccagttatgt gtgctcagga 
961  cttgttggag acacacccag aaaaaacgac agctccagca gtagccattg cttggatcct 
1021 aacaatgagg aaggtggtca tggagtgaaa ggctgggcct ttgatgatgg aaatgacgtg 
1081 tggatgggaa gaacgatcag cgagaagtta cgctcaggat atgaaacctt caaagtcatt 
1141 gaaggctggt ccaaacccaa ctccaaattg cagataaata ggcaagtcat agttgacaga 
1201 ggtaataggt ccggttattc tggtattttc tctgttgaag gcaaaagctg catcaatcgg 
1261 tgcttttatg tggagttgat aaggggaagg aaacaggaaa ctgaagtctt gtggacctca 
1321 aacagtattg ttgtgttttg tggcacctca ggtacatatg gaacaggctc atggcctgat 
1381 ggggcggaca tcaatctcat gcctatataa 
 
A/Illinois/14/2008 (H3N2) 
1    atgaatccaa atcaaaagat aataacgatt ggctctgttt ctctcaccat ttccacaata 
61   tgcttcttca tgcaaactgc catcttgata actactgtaa cattgcattt caagcaatat 
121  gaattcaact cccccccaaa caaccaagtg atgctgtgtg aaccaacaat aatagaaaga 
181  aacataacag agatagtgta tctgaccaac accaccatag agaaggaaat atgccccaaa 
241  ctagcagaat acagaaattg gtcaaagccg caatgtgaca ttacaggatt tgcacctttt 
301  tctaaggaca attcgattag gctttccgct ggtggggaca tctgggtgac aagagaacct 
361  tatgtgtcat gcgatcctga caagtgttat caatttgccc tcggacaggg aacaacacta 
421  aacaacgtgc attcaaatga cacagtacgt grtaggaccc cttatcggac cctattgatg 
481  aatgagttag gtgttccttt tcatctgggg accaagcaag tgtgcatagc atggtccagc 
541  tcaagttgtc acgatggaaa agcatggctg catgtttgta taacggggga tgataaaaat 
601  gcaactgcta gcttcattta caatgggagg cttgtagata gtattgtttc atggtccaag 
661  gaaattctca ggacccagga gtcagaatgc gtttgtatca atggaacttg tacagtagta 
721  atgactgatg ggagtgcttc aggaaaagct gatactaaaa tactattcat tgaggagggg 
781  aaaatcgttc atactagcac attgtcagga agtgctcagc atgtcgagga gtgctcctgc 
841  tatcctcgat atcctggtgt cagatgtgtc tgcagagaca actggaaagg ctccaatagg 
901  cccatcgtag atataaacat aaaggatcat agcattgttt ccagttatgt gtgttcagga 
961  cttgttggag acacacccag aaaaaacgac agctccagca gtagccattg tttggatcct 
1021 aacaatgaag aaggtggtca tggagtgaaa ggctgggcct ttgatgatgg aaatgacgtg 
1081 tggatgggaa gaacgatcag cgagaagtca cgcttagggt atgaaacctt caaagtcatt 
1141 gaaggctggt ccaaccctaa gtccaaattg cagataaata ggcaagtcat agttgacaga 
1201 ggtgataggt ccggttattc tggtattttc tctgttgaag gcaaaagctg catcaatcgg 
1261 tgcttttatg tggagttgat aaggggaaga aaagaggaaa ctgaagtctt gtggacctca 
1321 aacagtattg ttgtgttttg tggcacctca ggtacatatg gaacaggctc atggcctgat 
1381 ggggcggaca tcaatctcat gcctatataa 
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A/Oklahoma/1806/2008 (H3N2) 
 
1    aataacgatt ggctctgttt ctctcaccat ttccacaata tgcttcttca tgcaaattgc 
61   catcttgata actactgtaa cattgcactt caagcaatat gaattcaact cccccccaaa 
121  caaccaagtg atgctgtgtg aaccaacaat aatagaaaga aacataacag agatagtgta 
181  tctgaccaac accaccatag agaaggaaat atgccccaaa ctagcagaat acagaaattg 
241  gtcaaagccg caatgtgaca ttacaggatt tgcacctttt tctaaggaca attcgattag 
301  gctttctgct ggtggggaca tctgggtgac aagagaacct tatgtgtcat gcgatcctga 
361  caagtgttat caatttgccc ttggacaggg aacaacacta aacaacgtgc attcaaatga 
421  cacagtacgt ggtaggaccc cttatcggac cctattgatg aatgagttag gtgttccttt 
481  tcatctgggg accaagcaag tgtgcatagc atggtccagc tcaagttgtc accatggaaa 
541  agcatggctg catgtttgtc taacggggga tgataaaaat gcaactgcta gcttcattta 
601  caatgggagg cttgtagata gtattgtttc atggtccaaa gacatcctca ggacccagga 
661  gtcagaatgc gtttgtatca atggaacttg tacagtagta atgactgatg ggagtgcttc 
721  aggaaaagct gatactaaaa tactattcat tgaggagggg aaaatcgttc atactagcac 
781  attgtcagga agtgctcagc atgtcgagga gtgctcctgc tatcctcgat atcctggtgt 
841  cagatgtgtc tgcagagaca actggaaagg ctccaatagg cccatcgtag atataaacat 
901  aaaggatcat agcattgttt ccagttatgt gtgttcagga cttgttggag acacacccag 
961  aaaaaacgac agctccagca gtggccattg tttggatcct aacaatgaag aaggtggtca 
1021 tggagtgaaa ggctgggcct ttgatgatgg aaatgacgng tggatgggaa gaacgatcag 
1081 cgagaagtca cgcttagggt atgaaacctt taaagtcatt gaaggctggt ccaaccctaa 
1141 gtccaaattg cagataaata ggcaagtcat agttgacaga ggtaataggt ccggttattc 
1201 tggtattttc tctgttgaag gcaaaagctg catcaatcgg tgcttttatg tggagttgat 
1261 aaggggaaga aaagaggaaa ctgaagtctt gtggacctca aacagtattg ttgtgttttg 
1321 tggcacctca ggtacatatg gaacaggctc atggcctgat ggggcgga 
 
 
Influenza A virus (A/California/07/2009(H1N1)) Pandemic: 
1    atgaatccaa accaaaagat aataaccatt ggttcggtct gtatgacaat tggaatgg 
61   aacttaatat tacaaattgg aaacataatc tcaatatgga ttagccactc aattcaactt 
121  gggaatcaaa atcagattga aacatgcaat caaagcgtca ttacttatga aaacaacact 
181  tgggtaaatc agacatatgt taacatcagc aacaccaact ttgctgctgg acagtcagtg 
241  gtttccgtga aattagcggg caattcctct ctctgccctg ttagtggatg ggctatatac 
301  agtaaagaca acagtgtaag aatcggttcc aagggggatg tgtttgtcat aagggaacca 
361  ttcatatcat gctccccctt ggaatgcaga accttcttct tgactcaagg ggccttgcta 
421  aatgacaaac attccaatgg aaccattaaa gacaggagcc catatcgaac cctaatgagc 
481  tgtcctattg gtgaagttcc ctctccatac aactcaagat ttgagtcagt cgcttggtca 
541  gcaagtgctt gtcatgatgg catcaattgg ctaacaattg gaatttctgg cccagacaat 
601  ggggcagtgg ctgtgttaaa gtacaacggc ataataacag acactatcaa gagttggaga 
661  aacaatatat tgagaacaca agagtctgaa tgtgcatgtg taaatggttc ttgctttact 
721  gtaatgaccg atggaccaag taatggacag gcctcataca agatcttcag aatagaaaag 
781  ggaaagatag tcaaatcagt cgaaatgaat gcccctaatt atcactatga ggaatgctcc 
841  tgttatcctg attctagtga aatcacatgt gtgtgcaggg ataactggca tggctcgaat 
901  cgaccgtggg tgtctttcaa ccagaatctg gaatatcaga taggatacat atgcagtggg 
961  attttcggag acaatccacg ccctaatgat aagacaggca gttgtggtcc agtatcgtct 
1021 aatggagcaa atggagtaaa agggttttca ttcaaatacg gcaatggtgt ttggataggg 
1081 agaactaaaa gcattagttc aagaaacggt tttgagatga tttgggatcc gaacggatgg 
1141 actgggacag acaataactt ctcaataaag caagatatcg taggaataaa tgagtggtca 
1201 ggatatagcg ggagttttgt tcagcatcca gaactaacag ggctggattg tataagacct 
1261 tgcttctggg ttgaactaat cagagggcga cccaaagaga acacaatctg gactagcggg 
1321 agcagcatat ccttttgtgg tgtaaacagt gacactgtgg gttggtcttg gccagacggt 
1381 gctgagttgc catttaccat tgacaagtaa 
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A/Aragon/RR3218/2008(H1N1): Proficiency panel Swine flu control. 
1   aatggaacca ttaaggacag aagtccatat cgaaccttaa tgagctgtcc tattggtgaa 
61  gtcccttctc catacaactc aaggtttgag tcagtcgctt ggtcagcaag tgcttgccat 
121 gatggtacca gttggctaac aattggaatt tctggcccag ataatggggc agtggctgtg 
181 ctgaaataca acggcataat aacagacact atcaagagtt ggagaaacaa catattaaga 
241 acacaagagt ctgaatgtgc atgcgtgaat ggttcttgct ttactataat gaccgatgga 
301 ccaagtaatg ggcaggcctc atacaagatc tttaagatag aaagggggaa agtagtaaaa 
361 tcagtcgagt tgaatgcccc taattaccac tatgaggaat gctcctgtta tcctgagtct 
421 ggtgaaatta catgtgtgtg cagagataat tggcatggct caaatcggcc atgggtgtct 
481 ttcaatcaga atctggaata taaaatagga tacatatgca gtgggatttt cggagacaat 
541 ccgcgcccta atgatggaac aggcagttgt ggcccagtac tctctaatgg agcaaatggg 
601 gtaaaaggat tttcatttaa atacggcaat ggtgtttgga tagggagaac taaaagcact 
661 agctcaagga gcggttttga gatgatttgg gatccaaatg gatggaccag aacagacgat 
721 aatttctcag taaagcaaga tatcatagga atgactcatt ggtcaggata tagcgggagt 
781 tttgctc 
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Appendix II. Primers: 
A(H1N1): 151 – GAC → GAA - AGGAC/AAG 
 HuH1N1-151-F425  5’-ACAAACATTCAAATGGRACCG-3’ 
 HuH1N1-151-R521-biot 5’-CTGACCATGCAACTGATTCAA-3’ 
 Strand binding point  3’- GACTGGTACGTTGACTAAGTT-5’  
 HuH1N1- 151-F425-seq 5’-ACAAACATTCAAATGGRACCG-3’ 
  
A(H1N1): 274 – CAT → TAT - TTTC/TATT 
 HuH1N1- 274-F770  5’-AGATCGAGAAGGGGAAGGTTACTA-3’ 
 HuH1N1- 274-R882-biot 5’-GTCYCTGCATACACACATCACT-3’ 
 Strand binding point  3’-CAGYGACGTATGTGTGTAGTGA-5’ 
 HuH1N1-274-F807-seq  5’-AAATGCACCCAAT-3’ 
Colindale Primers 
A(H1N1): 274 – CAT → TAT - TTTC/TATT 
 HuH1N1- 274-For  5’-GGAGCCGTGGCTGTACTAAAATA-3’ 
 HuH1N1- 274-R882-biot 5’-CCACGTTTTGATTAAAAGACACC-3’ 
 Strand binding point  3’-GGTGTCTTTTAATCAAAACGTGG-5’ 
 HuH1N1-274-F807-seq  5’-AGTTGAATGCACCCAAT-3’ 
 
A(H3N2): 119 – TTC → TAC – AGGTT/ACTCT 
 HuH3N2-F333-biot  5’-TGCGGACATCTGGGTGACA-3’ 
 HuH3N2-R914   5’-ATATCTACTATGGGCCTATTGGA-3’ 
 Strand binding point  3’-TATAGATGATACCCGGATAACCT-5’ 
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 HuH3N2-R377-seq  5’-GGATCGCATGACACATA-3’ 
 Strand binding point  3’-CCTAGCGTACTGTGTAT-5’ 
 
A(H3N2): 151 – V- GAT → GTT, A – GAT → GCT, N – GAT → AAT 
   V – TGA/TTAG, A – TGA/CTAG, N – TG/AATAG 
 HuH3N2-F423  5’-CAACGTGCATTCAAATGACAC-3’ 
 HuH3N2-R567-biot  5’-CCAYGCTTTYCCATCRTG-3’ 
 Strand binding point  3’- GGTYCGAAAYGGTAGRAC-5’ 
 HuH3N2-F423-seq  5’-CAACGTGCATTCAAATGACAC-3’ 
 
A(H3N2): 292/294 – 292 – TCT → TTT – GTCTC/TTTC 
 HuH3N2-F333-biot  5’-TGCGGACATCTGGGTGACA-3’ 
 HuH3N2-R914   5’-ATATCTACTATGGGCCTATTGGA-3’ 
 Strand binding point              3’- TATAGATGATACCCGGATAACCT-5’ 
 HuH3N2- R905-seq  5’-ATGGGCCTATTGCAGCC-3’ 
 Strand binding point              3’-TACCCGGATAACGTCGG-5’ 
 
Pandemic Influenza A(H1N1) 2009: 274 – CAC → TAC - ATC/TACTATGAG 
 Uni-sw-N1-B-F780  5’-GGGGAAGATTGTYAAATCAGTYGA -3’ 
 Uni-sw-N1-B-R1273-biot 5’-CWACCCAGAARCAAGGYCTTATG-3’ 
 Strand binding point  3’- GWTGGGTCTTRGTTCCYGAATAC-5’ 
 Uni-sw-N1-B-F804-seq  5’-GYTGAATGCMCCTAATT -3’ 
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Appendix III. Worksheets: 
Worksheet 1: 
 Volume n+ 1 
2x Reaction mix 25µl   
Forward primer (20µM) 1µl   
Reverse primer (20µM) 1µl   
Superscript III RT/Platinum Taq Mix 2µl   
RNAse-free water 16µl   
Total 45 µl  
 
Add 5µl of eluate to 45µl of mastermix. 
 
1. 9. 17. 25. 33. 41. 
2. 10. 18. 26. 34. 42. 
3. 11. 19. 27. 35. 43. 
4. 12. 20. 28. 36. 44. 
5. 13. 21. 29. 37. 45. 
6. 14. 22. 30. 38. 46. 
7. 15. 23. 31. 39. 47. 
8. 16. 24. 32. 40. 48. 
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Sequencing worksheet: 
Immobilisation mix: 
Reagent Volume n+1 
Streptavidin Beads 3ul  
Binding buffer 40ul  
Water 17ul  
Total 60ul  
Add 20ul of amplified product to 60ul immobilisation mix. 
Reagent Volume for 10 
reactions 
Reactions 
Sequencing primer (100uM) 2ul  
Annealing buffer 438ul  
Total 440ul  
 
Cartridge Volumes: 
 G  
C  T 
S A E 
 
1. 9. 17. 25. 33. 41. 
2. 10. 18. 26. 34. 42. 
3. 11. 19. 27. 35. 43. 
4. 12. 20. 28. 36. 44. 
5. 13. 21. 29. 37. 45. 
6. 14. 22. 30. 38. 46. 
7. 15. 23. 31. 39. 47. 
8. 16. 24. 32. 40. 48. 
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New worksheet 18/04/10 
 Volume n+ 1 
2x Reaction mix 25µl  
Forward primer (20µM) 1µl  
Reverse primer (20µM) 1µl  
Superscript III RT/Platinum Taq Mix 1µl  
RNAse-free water 12µl  
Total 40 µl  
 
Add 10µl of eluate to 40µl of mastermix. 
 
1. 9. 17. 25. 33. 41. 
2. 10. 18. 26. 34. 42. 
3. 11. 19. 27. 35. 43. 
4. 12. 20. 28. 36. 44. 
5. 13. 21. 29. 37. 45. 
6. 14. 22. 30. 38. 46. 
7. 15. 23. 31. 39. 47. 
8. 16. 24. 32. 40. 48. 
 
 
 
 
 
 
 105 
 
New worksheet 12/05/10: 
 Volume n+ 1 
2x Reaction mix 25µl  
Forward primer (20µM) 1µl  
Reverse primer (20µM) 1µl  
Superscript III RT/Platinum Taq Mix 1µl  
RNAsin 1µl  
RNAse-free water 6µl  
Total 35µl  
 
Add 15µl of eluate to 35µl of mastermix. 
 
1. 9. 17. 25. 33. 41. 
2. 10. 18. 26. 34. 42. 
3. 11. 19. 27. 35. 43. 
4. 12. 20. 28. 36. 44. 
5. 13. 21. 29. 37. 45. 
6. 14. 22. 30. 38. 46. 
7. 15. 23. 31. 39. 47. 
8. 16. 24. 32. 40. 48. 
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QIAGEN One step master mix worksheet: 
 Volume N+2 
QIAGEN One step RT-PCR Buffer 
5x 
5µl  
Forward primer (20µM) 1µl  
Reverse primer (20µM) 1µl  
dNTP mix 1µl  
QIAGEN One-step RT-PCR 
Enzyme mix 
1 µl  
RNAse-free water 6µl  
Total 15 µl  
 
Add 10µl of eluate to 15µl of mastermix. 
 
1. 9. 17. 25. 33. 41. 
2. 10. 18. 26. 34. 42. 
3. 11. 19. 27. 35. 43. 
4. 12. 20. 28. 36. 44. 
5. 13. 21. 29. 37. 45. 
6. 14. 22. 30. 38. 46. 
7. 15. 23. 31. 39. 47. 
8. 16. 24. 32. 40. 48. 
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Appendix IV. Raw data: 
H1H1 pre 2009 samples: 
  Typing  H274 Colindale 
3 H1 F   
4 H1 R (T 99% / C 1%)   
25 H1 R (T 96% / C 4%)   
27 H1 R (T 98% / C 2%)   
34 H1 R (T 99% / C 1%)   
35 H1 R (T 97% / C 3%)   
38 H1 R (T 99% / C 1%)   
47 H1 R (T 99% / C 1%) R (T 100%) 
52 H1 R (T 99% / C 1%) R (T 100%) 
53 H1 R (T 94% / C 6%) R (T 100%) 
54 H1 R (T 98% / C 2%) R (T 100%) 
67 H1 R (T 99% / C 1%) R (T 100%) 
70 H1 R (T 99% / C 1%) R (T 100%) 
74 H1 R (T 99% / C 1%) R (T 100%) 
76 H1 F R (T 100%) 
 
H3N2 samples: 
 Typing  CT E119 R292 D151 E119 Qiagen 
2 H3 39 F F F S (T 95%/ A 5%) 
5 H3   F   F   
6 H3 38 S (T 100%) F   S (T 95%/ A 5%) 
7 H3 40 F   F S (T 95%/ A 5%) 
8 H3 40 F F F   
9 H3 39 F F F   
10 H3 32 S (T 96%/A 4%) F F   
11 H3 36 S (T 100%) F F   
14 H3 30 S (T 100%) S S   
26 H3   S (T 87.5%/ A12.5%) S S   
28 H3 29 S (T 97% / A 3%) S S S (T 95%/ A 5%) 
29 H3 27 S (T 100%)   F S (T 95%/ A 5 %) 
30 H3 38 F F F   
31 H3 26 S (T 87% /A 13%) F F   
32 H3   S (T 100%)   S   
33 H3 37 S (T 100%) S F   
36 H3 36 F   F   
37 H3 32 S (T 92% / A 8%) F F   
39 H3 35 F F F   
40 H3 38 F   F S (T 100%) 
41 H3 28 S (T 100%)   S S (T 95%/ A 5%) 
42 H3 30 S (T 97% / A 3%) S S S (T 95%/ A 5%) 
44 H3 31 S? (T 79% / A 21%) F F   
45 H3 32 S (T 100%)       
46 H3 30 S (T 90% / A 10%)       
48 H3 27 S (T 97% / A 3%) S     
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49 H3 36 S (T 88% / A 12%) F     
50 H3 34 S? (T 69% / A 31%) F     
51 H3 25 S (T 96% / 4%)   S   
55 H3 37 S (T 100%) F     
56 H3 39 F F     
57 H3 32 S (T 100%) S     
58 H3 33 S (T 86% / A 14%) S     
59 H3 36 F F     
60 H3 35 F F S   
61 H3 27 S (T 96% / A 4%) S     
62 H3 39 F F     
63 H3 37 S (T 100%) F     
64 H3 41 F F     
65 H3 36 F F     
66 H3 30 S (T 100%) S     
68 H3 31 S? (T 72% / A 28%) F     
69 H3 26 S (T 97% / A 3%) S     
71 H3 25 S (T 97% / A 3%) S     
72 H3 34 S (T 100%) S     
73 H3 30 S (T 100%) F     
75 H3 37 S (T 100%) S     
77 H3 31 S? (T 82% / A 18%) F     
78 H3 26 S (T 95% / A 5%) S     
79 H3   S (T 93% / A 7%) F     
 
H1N1pdm09 samples: 
   Typing  CT Pandemic H274Y 
12  H1 (Swine)   S (T12%/C 88%) 
13  H1 (Swine)   S (T 3%/C 97%) 
15  H1 (Swine)   S (T 2%/ C 98%) 
16  H1 (Swine)   S (T 4%/ C 96% 
17  H1 (Swine)   S (T 4%/ C 96% 
18  H1 (Swine)   S (T 2%/ C 98%) 
19  H1 (Swine)   S (T 2%/ C 98%) 
20  H1 (Swine)   S (T 2%/ C 98%) 
21  H1 (Swine)   S (T 3%/ C 97%) 
22  H1 (Swine)   S (T 3%/ C 97%) 
23  H1 (Swine)   S (T 3%/ C 97%) 
24  H1 (Swine)   S (T 5%/ C 95%) 
81  H1 (Swine)   SQA 
82  H1 (Swine)   SQA 
83  H1 (Swine)   S (T 4%/ C 96%) 
84  H1 (Swine)   S (T 3%/ C97%) 
85  H1 (Swine)   SQA 
86  H1 (Swine)   SQA 
87  H1 (Swine)   SQA 
88  H1 (Swine)   SQA 
89  H1 (Swine)   SQA 
90  H1 (Swine)   SQA 
 109 
 
A  H1 (Swine) 42 F 
B  H1 (Swine)   S (C 100%) 
C  H1 (Swine) 30 S (C 100%) 
D  H1 (Swine)   S (C 100%) 
E  H1 (Swine) NEG F 
F  H1 (Swine)   S (C 100%) 
G  H1 (Swine)   S (T 3%/ C 97%) 
H  H1 (Swine)   S (C 100%) 
92  H1 (Swine)   S (T 5%/ C 95%) 
93  H1 (Swine)   F 
94  H1 (Swine)   S (T 2%/ C 98%) 
95  H1 (Swine)   S (T 5%/ C 95%) 
96  H1 (Swine)   S (T 5%/ C 95%) 
97  H1 (Swine)   S (T 5%/ C 95%) 
98  H1 (Swine)   S (T 2%/ C 98%) 
99  H1 (Swine)   F 
100  H1 (Swine)   S (T 3%/ C 97%) 
101  H1 (Swine)   S (T 3%/ C 97%) 
102  H1 (Swine)   S (T 2%/ C 98%) 
103  H1 (Swine)   S (T 3%/ C 97%) 
104  H1 (Swine)   S (T 3%/ C 97%) 
105  H1 (Swine)   S (T 9%/ C 91%) 
106  H1 (Swine)   S (T 2%/ C 98%) 
107  H1 (Swine)   S (T 4%/ C 96%) 
108  H1 (Swine)   S (T 5%/ C 95%) 
109  H1 (Swine)   S (T 5%/ C 95%) 
110  H1 (Swine)   S (T 7%/ C 93%) 
111  H1 (Swine)   S (T 2%/ C 98%) 
112  H1 (Swine)   S (C 100%) 
113  H1 (Swine)   S (T 3%/ C 97%) 
114  H1 (Swine)   S (T 5%/ C 95%) 
115  H1 (Swine)   F 
116  H1 (Swine)   F 
117  H1 (Swine)   S (T 3%/ C 97%) 
118  H1 (Swine)   F 
119  H1 (Swine)   F 
130  H1 (Swine)   R (T 92%/ C 8%) 
131  H1 (Swine)   R (T 100%) 
132  H1 (Swine)   F 
133  H1 (Swine)   F 
134  H1 (Swine)   F 
135  H1 (Swine)   F 
136  H1 (Swine)   F 
137  H1 (Swine)   F 
138  H1 (Swine)   S (C 100%) 
139  H1 (Swine)   R (T 42%/ C 58%) 
140  H1 (Swine)   S (C 100%) 
141  H1 (Swine)   R (T 49% / C 51%) 
142  H1 (Swine)   S (T 1%/ C 99%) 
143  H1 (Swine)   S (C 100%) 
144  H1 (Swine)   S (T 1%/ C 99%) 
145  H1 (Swine) 26 S (C 100%) 
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146  H1 (Swine) 31 S (C 100%) 
147  H1 (Swine) 33 F 
148  H1 (Swine) 36 F 
149  H1 (Swine) 33 F 
150  H1 (Swine) 25 S (T 3%/ C 97%) 
151  H1 (Swine) 35 S (T 7%/ C 93%) 
152  H1 (Swine) 26 S (T 2%/ C 98%) 
153  H1 (Swine) 27 S (T 1%/ C 99%) 
154  H1 (Swine) 26 S (T 1%/ C 99%) 
155  H1 (Swine) 32 F 
156  H1 (Swine) 28 S (C 100%) 
157  H1 (Swine) 36 F 
158  H1 (Swine) 28 S (T 1%/ C 99%) 
159  H1 (Swine) 29 S (T 2%/ C 98%) 
160  H1 (Swine) 37 F 
161  H1 (Swine) 29 S (T 4%/ C 96%) 
162  H1 (Swine) 20 S (T 2%/ C 98%) 
163  H1 (Swine) 28 S (C 100%) 
164  H1 (Swine) 29 S (C 100%) 
165  H1 (Swine) 28 S (C 100%) 
166  H1 (Swine) 23 S (T 3%/ C 97%) 
167  H1 (Swine) 18 S (T 1%/ C 99%) 
168  H1 (Swine) 21 S (T 1%/ C 99%) 
169  H1 (Swine) 23 S (T 7%/ C 93%) 
170  H1 (Swine) 35 S (T 2%/ C 98%) 
171  H1 (Swine) 33 S (T 9%/ C 91%) 
172  H1 (Swine) 35 S (T 4%/ C 96%) 
173  H1 (Swine)   R (T 100%) 
174  H1 (Swine)   S (T 3%/ C 97%) 
175  H1 (Swine)   S (T 4%/ C 96%) 
176  H1 (Swine)   S (C 100%) 
177  H1 (Swine)   S (T 2%/ C 98%) 
178  H1 (Swine)   F 
179  H1 (Swine)   S (T 10%/ C 90%) 
180  H1 (Swine)   S (T 7%/ C 93%) 
181  H1 (Swine)   S (T 11%/ C 89%) 
182  H1 (Swine)   S (T 8%/ C 92%) 
183  H1 (Swine)   S (T 1%/ C 99%) 
184  H1 (Swine)   S (C 100%) 
185  H1 (Swine)   S (T 1%/ C 99%) 
186  H1 (Swine)   S (C 100%) 
187  H1 (Swine)   S (C 100%) 
188  H1 (Swine)   S (C 100%) 
189  H1 (Swine)   F 
190  H1 (Swine)   S (T 2%/ C 98%) 
          
  
prof panel 
2010 3 H1 (Swine)   S (T 4%/ C 96%) 
  
prof panel 
2010 4 H1 (Swine)   F 
  
prof panel 
2010 7 H1 (Swine)   R (T 100%) 
  prof panel H1 (Swine)   R (T 76%/ C 24%) 
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2010 8 
          
120 QCMD INF03 H1     
121 QCMD INF09 H1     
122 
QCMD 
INFHT06 H1     
123 
QCMD 
INFHT09 H1     
124 QCMD INF02 H1 (Swine)   
S (T 3.5%/ C 
96.5%) 
125 QCMD INF05 H1 (Swine)   S (T 1%/ C 99%) 
126 QCMD INF08 H1 (Swine)   S (T 4%/ C 96%) 
127 QCMD INF11 H1 (Swine)   S (T 4%/ C 96%) 
128 
QCMD 
INFHT03 H1 (Swine)   S (T 2%/ C 98%) 
129 
QCMD 
INFHT08 H1 (Swine)   S T 6%/ C 94%) 
 
